WO1996002576A1 - Anticorps humain reconstitue contre l'interleukine-8 humaine - Google Patents
Anticorps humain reconstitue contre l'interleukine-8 humaine Download PDFInfo
- Publication number
- WO1996002576A1 WO1996002576A1 PCT/JP1995/001396 JP9501396W WO9602576A1 WO 1996002576 A1 WO1996002576 A1 WO 1996002576A1 JP 9501396 W JP9501396 W JP 9501396W WO 9602576 A1 WO9602576 A1 WO 9602576A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- region
- chain
- amino acid
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a complementarity determining region (CDR) and a variable region (V region) of a mouse monoclonal antibody against human interleukin-18 (IL-8), and human / mouse against human IL-18.
- CDR complementarity determining region
- V region variable region
- the skimmer antibody, the human light chain (L chain) variable region and the human heavy chain (HID variable region complementarity determining region (CDR)) are replaced by the mouse monoclonal antibody to human IL-18 CDR.
- the present invention further provides a DNA encoding the above antibody or a part thereof
- the present invention further provides a vector comprising the DNA.
- the present invention relates to an expression vector, and a host transformed with the vector.
- the present invention further provides a method for producing a chimeric antibody against human IL-18, and a reconstituted human against IL-18. Antibody And a method of manufacturing the same.
- Interlokin-1 8 is found in culture supernatants of monocytes stimulated with lipopolysaccharide (LPS) and is derived from monocyte-derivedneutrophilchemotactic factor (MDNCF) or neutrophi-1 activating protein-1 (NAP-). 1) It is a migratory sitekine (chemokine), which was called etc. IL-18 is produced by various cells and acts on polymorphonuclear leukocytes and lymphocytes to chemotaxis along their concentration gradient. It has nature. It not only induces neutrophils to migrate, but also has the effect of activating neutrophil functions such as degranulation, release of active oxygen, and enhanced adhesion to endothelial cells. ing.
- LPS lipopolysaccharide
- MDNCF monocyte-derivedneutrophilchemotactic factor
- NAP- neutrophi-1 activating protein-1
- Inflammatory diseases more specifically respiratory diseases such as pulmonary fibrosis, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, sarcoidosis, pleuritic pleurisy, and skin diseases such as psoriasis), and In diseases such as chronic rheumatic rheumatitis, Crohn's disease, and ulcerative colitis, leukocyte infiltration is pathologically recognized at the lesion site.
- IL-18 was detected in test substances derived from patients with these diseases, and is considered to play a central role in inflammation.
- anti-human IL-18 antibodies other than WS-4 A. 5.1.2.14 (Bol an, A. M. et al., J. Clin. Invest., 89, 1 2 5 7-1 2 6 7, 1 9 9 2), anti-P ep-1 antibody or anti-P ep — 3 antibody or D MZ disclosed in international patent application W 0 9-0 4 3 7 2 C7 (ulligan, S. et al., J. Immun 01. 150.55, 855-55, 595, 1993) and the like are known.
- pulmonary ischemia / reperfusion injury (Sekido, N. et al., Nature, 365, 65) was achieved by administering mouse monoclonal antibody WS-4. 4-65 7, 1993), LPS-induced dermatitis (Harada, A. et al., Internal 1.Immunol., 5, 681-69 0, 1993), LPS or interlokine-1 (IL-1) -induced arthritis (Akahoshi, T. et al., Lymphokine and Cytokine
- Rabbits also have a homologue of human IL-18 (homo 1 ogue), which is called Egret IL-8. It has been shown that the mouse monoclonal antibody WS-14 cross-reacts with Egret IL-8 and inhibits the binding of Eg IL-8 to Eg neutrophils (Harada, A. et al., I nternatl. I mmunol., O, 681-690, 1993), which suggests that the anti-human IL-18 antibody is useful as a therapeutic agent for the treatment of inflammatory diseases in humans. And suggests.
- Monoclonal antibodies derived from mammals other than humans are highly immunogenic (sometimes referred to as "antigenic") in humans and, for this reason, their medical characteristics in humans. Therapeutic value is limited. For example, even if a mouse antibody is administered to a human, the mouse antibody can be metabolized as a foreign substance. Therefore, the half-life of the mouse antibody in the human is relatively short, and the expected effect cannot be sufficiently exerted. In addition, human anti-mouse antibodies raised against the administered mouse antibodies will elicit inconvenient and dangerous immune responses to the patient, such as serum sickness or other allergic reactions. And for this reason, humans cannot receive frequent mouse antibodies.
- Mouse antibodies can be humanized in two ways. A simpler method is to prepare chimeric antibodies in which the variable region (V region) is originally derived from a mouse monoclonal antibody and the constant region (C region) is derived from an appropriate human antibody. is there. Since the resulting chimeric antibody has the complete variable region of the original mouse antibody, it can be expected to bind to the antigen with the same specificity as the original mouse antibody.
- V region variable region
- C region constant region
- chimeric antibodies have less immunogenicity than the original mouse antibodies because the ratio of protein sequences derived from animals other than the peptide is substantially reduced compared to the original mouse antibodies. Expected to be low. Chimeric anti-tumours bind better to antigens and are less immunogenic, but may still generate an immune response against the mouse variable region (LoBug1io, AF, et al. roc.N atl.A cad.S ci.USA, 86, 4 22 0-4 2 2 2, 1 9 8 9
- the second G method to transform mouse antibodies into humans More complex ? However, it significantly reduces the potential immunogenicity of mouse antibodies.
- a “reshaped” human variable region is prepared by transplanting only a competibility determining region (CDR) from a mouse antibody variable region into a human variable region.
- CDR competibility determining region
- the structure of the framework region (FR) supporting the CDR may be changed.
- CDR portion derived from the protein sequence other than human in the finally reconstituted human antibody is CDR and only a part of FR.
- CDR is composed of hypervariable protein sequences, which do not show species-specific sequences. For this reason, reshaped human antibodies carrying mouse CDR should no longer be more immunogenic than native human antibodies containing human CDR.
- reconstituted human antibodies are expected to be useful for therapeutic purposes, but no reconstituted human antibodies against human IL-8 are known. Furthermore, there is no uniform method that can be universally applied to any antibody in a method for producing a reshaped human antibody. Therefore, in order to produce a reshaped human antibody exhibiting a sufficient binding activity or a neutralizing activity for a specific antigen, various measures are required (for example, Sat0, K. et al.). , 53, 851-85 6, 1993). Therefore, the present invention provides an antibody having low immunogenicity against human IL-18.
- the present invention provides a reshaped human antibody against human IL-18.
- the present invention also provides a human / mouse chimeric antibody useful in the process of producing the reshaped human antibody.
- the present invention further provides fragments of the reconstituted human anti-cancer.
- the present invention provides an expression system for producing chimeric antibodies, reshaped human antibodies, and fragments thereof.
- the present invention further provides
- the present invention provides
- the present invention further provides
- L ⁇ comprising the human L chain C region and the L protein V region of a mouse monoclonal antibody against human IL-18;
- H chain comprising the human H chain C region, and the H chain V region of a mouse monoclonal antibody against human IL-18;
- the present invention further provides
- an L chain comprising a human L chain C region and an L chain V region of a mouse monoclonal antibody against human IL-18;
- a chimeric antibody against human IL-18 is provided.
- the present invention further provides
- the present invention further provides
- an L protein comprising the human L chain C region, and the LIV region of mouse monoclonal antibody WS-4 against human IL-18;
- mice L chain comprising the mouse L chain V region of mouse monoclonal antibody W S-4 against human L chain C region and mouse IL-8;
- a chimeric antibody against human IL-18 is provided.
- the present invention further provides
- the present invention further provides
- the present invention further provides
- FR framework region of the human L chain V region
- the present invention further provides
- human L chain C region (2) an antibody against human IL-18 comprising: an L chain V region comprising an L chain CDR of a mouse monoclonal antibody against human L chain FR and human IL-8; Constituent human light chains; and
- an H chain V region comprising the H chain CDR of a mouse monoclonal antibody against human H chain FR and human IL-18; and reconstitution of an antibody against human IL-18. Provides a human heavy chain.
- the present invention further provides
- H chain comprising a human H chain FR and a mouse monoclonal antibody H chain CDR against human IL-18;
- the present invention further provides
- mouse H monoclonal V domain against mouse IL-8 comprising a CDR of the H chain V domain of W S-4; and a reshaped human H domain of an antibody against human IL-8.
- the present invention further provides
- an H chain V region comprising an H chain CDR of a mouse monoclonal antibody WS— against human H chain FR and human IL-8; Provides antibody reconstitution human H ⁇ .
- the present invention further provides
- a reshaped human antibody against human IL-18 is provided.
- Examples of the human LFR include those having the following amino acid sequence.
- Examples of the human H chain FR include those having the following amino acid sequence.
- FR1 Glu Va 1 G 1 n Leu Leu G 1 u Ser Gl G1 Gl Leu Val G in Pro G 1 y Gly Ser Leu Arg Leu Ser Cys A 1 a A 1 a Ser G 1 y Phe Thr Phe Ser
- the present invention also covers DNA encoding the polypeptides or fragments thereof constituting the various antibodies.
- the present invention also relates to a vector comprising the above DNA, for example, an expression vector.
- the present invention further provides a host transformed with the above vector.
- the present invention further provides methods for producing chimeric antibodies against human IL-8 and fragments thereof, and methods for producing reshaped human antibodies against human IL-18 and fragments thereof.
- FIG. 1 shows a human 'erogenation' factor—la (HEF—1a) promoter / enhancer useful for expression of the L chain and H chain of the antibody of the present invention, respectively.
- the expression vectors HEF-VL-gA: and HEF-VH-g-c1 are shown.
- Figure 2 shows the results of ELISA for confirming the binding ability of the chimeric WS-4 antibody (chL / chH) of the present invention produced in the culture supernatant of COS cells to human IL-8. This is the graph shown.
- FIG. 3 shows the first version of the H ⁇ V region of the reshaped human WS-4 antibody of the present invention, “a ⁇ RVH a) (A), and the reshaped human WS-4 antibody.
- FIG. 4 shows the L chain V region (RVLa) and the H chain V region (RVH a) of the reconstituted human WS-4 antibody of the present invention, and the chimera WS-4 antibody H chain V region (chH), respectively.
- chimera WS-4 antibody L-protein V region (chL) in COS cells and the ability to bind to human IL-18 and the amount of production were determined by using the chimera of the present invention produced in the culture supernatant of COS cells.
- FIG. 5 shows eight reconstituted human WS—4 antibodies (RVLa, RVLa / RVHb, RVLa) comprising the RVLa of the present invention produced in the culture supernatant of COS cells. / RVHc, RVLa / RVHd, RVLa / RVHe, RVLa / RVHf, RVLa / RVHg, RVLa / RVHh) to human IL-18.
- 4 is a graph showing the results of ELISA for comparison with the chimeric WS-4 antibody (chL / chH) of the present invention produced in the culture supernatant of Example 1.
- FIG. 6 shows eight reconstituted human WS-4 antibodies (RVLb / RVHa, RVLb / RVHb, RVLb) comprising the RVLb of the present invention produced during the eradication of COS cells.
- COS cells 4 is a graph showing the results of ELISA for comparison with the chimeric WS-4 antibody of the present invention (chLZchH) produced in the culture supernatant.
- Figure 7 shows the purified reconstituted human WS-4 antibody of the present invention, RVLa ZR.
- VH g average :: ' ⁇ RVL b ZRVH g O ⁇ .
- FIG. 3 is a graph showing the results of ELISA for comparison with the purified Chimera WS-4 antibody of the present invention (chL / chH).
- FIG. 3 is a graph showing the results of ligand-receptor single-binding inhibition assay for comparison with the chimeric WS-4 antibody of the present invention ((; 11 shi / (: 11-1)).
- a mouse monoclonal antibody against human IL-18 was used as a source of the gene. It is necessary to produce hybridomas that produce chromosomes. After extracting mRNA from the hybridoma, it is converted to single-stranded cDNA by a known method, and the target DNA is amplified using the polymerase chain reaction (PCR). can get.
- PCR polymerase chain reaction
- An example of a source of this gene is the hybridoma WS-4, which produces a mouse monoclonal antibody against human IL-18, produced by Ko, ⁇ -C. Et al. The method for producing this hybridoma is described in J. Immunol.Mehods, 19,
- the hybridoma cells are lysed by guanidinium thiosinate treatment and centrifuged by cesium chloride density gradient centrifugation.
- C hirg In. J. M. et al., Biochemistr :, '. 1S, 529-529, 1979) can obtain total RNA.
- RNase ribonuclease
- the methods already used to clone other protein genes such as surfactants in the presence of ribonuclease (RNase) inhibitors such as vanadium complexes, have been used. It is also possible to use a method of carrying out processing and phenol processing (Berger, S.L., et al., Biochemistry, 18: 51-43-514, 1979).
- oligo (dT) which is an oligonucleotide complementary to the P01yA chain located at the 3 'end of mRNA, was used as a primer, and The mRNA contained in the obtained total RNA can be treated with a reverse transcriptase to produce a single-stranded cDNA complementary to the mRNA (Larrick, JW). Et al., Bio ZTechnology. 7, 934-9338, 1989). At that time, a random primer may be used. When only mRNA is obtained, all RNA can be applied to an oligo dT cellulose column, and only mRNA having p01A $ 1 can be separated.
- cDNA encoding the V region is specifically amplified using the polymerase chain reaction (PCR) method.
- PCR polymerase chain reaction
- SEQ ID NOS: 11 types of oligonucleotide primers shown in 1-11 M0useKapP a Variable (MKV) and SEQ ID NO: 12 were used as the 5′-end primer and 3′-end primer, respectively, for the Mouse Kappa Constant (MKC).
- MKY 'image is hybridized with the DNA sequence encoding the C'-type L-chain leader sequence, and the MKY' image is hybridized with the DNA sequence.
- the MKC primer hybridizes with the DNA system K that encodes the mouse force saliva-type L chain C region.
- oligonucleotide primer shown in 5 is used as the 5 ′ unprimed primer and 3 ′ terminal primer, respectively.
- the MHV primer hybridizes with a DNA sequence encoding a mouse H chain leader sequence
- the MHC primer encodes a DNA encoding a mouse H chain C region. Hybridizes with the sequence.
- all 5 'terminal primers (MKV and MHV) have a sequence CTCGAC which provides a restriction enzyme Sa1I cleavage site near the 5' end, and all 3 'terminal primers
- the imers ( ⁇ 410 and ⁇ 1 ⁇ 1C) have a nucleotide sequence CCCGGG near the 5 'end that provides a restriction enzyme XmaI cleavage site. These restriction enzyme cleavage sites are used for subcloning DNA fragments encoding both V regions into respective cloning vectors. If these restriction sites are also present in the target DNA sequence encoding both V regions, other restrictions may be used so long as they are used to subclone the respective cloning vectors. It may be an enzyme cleavage site.
- the PCR amplification product was converted to a low-melting-point agarose gel or a column [kit for PCR product purification ( QIAGEN ⁇ Separation and purification are performed using a CRP urification Spin Kit: QIAGEN) and a DNA purification kit (GENECLEAN II: BI0101).
- the purified product is treated with the restriction enzymes SalI and Xma1 to obtain a DNA fragment encoding the desired V region of the mouse monoclonal antibody.
- an appropriate clone vector such as plasmid pUC19 is cut with the same restriction enzymes Sa1I and XmaI, and the DNA fragment is ligated enzymatically to this pUC19.
- a plasmid containing a DNA fragment encoding the target V region of the mouse monoclonal antibody is obtained.
- Sequencing of the cloned DNA can be performed according to any conventional method, for example, by using an automatic DNA sequencer (Applied BiosystemsInc.). Example 1 and Example 2 specifically describe the objective DNA closing and sequencing thereof.
- CDR Complementarity determination region
- the present invention further provides a super V region or complementarity determining region (CDR) of the V region of a mouse monoclonal antibody to human IL-18.
- CDR complementarity determining region
- the V regions of both the L ⁇ and H chains of the antibody form the antigen binding site. This region on the L and H chains has a similar basic structure.
- Both V regions constitute four framework regions of relatively conserved sequence, which are linked by three super-V regions or CDRs (Kabat, EA, et al. r S equencesof Proteinsof Immunological Interestj, USD ept.H ealthand Human S ervices 1 9 9 1) »
- Most of the four framework regions (FR) have a / 9-sheet structure, and the three CDRs form a loop. Where CDR is In some cases, a P- -port structure-part may be formed.
- the FRs keep the three CDRs very close sterically to each other, and together with the three CDRs in a pair, contribute to the formation of an antigen-binding site.
- the present invention also provides these CDRs useful as materials for humanized antibodies, and DNAs encoding them. By comparing these CDR regions with the known amino acid sequences of the V region, Kabat, EA, et al., "Sequences of Proteinsois".
- Immunu olog iCal l Inte r e s st can be determined, and this will be specifically described in the third embodiment.
- chimeric antibodies Prior to designing the reshaped human V region of the antibody against human IL-18, it is necessary to ensure that the CDRs used actually form the antigen-binding region. For this purpose, chimeric antibodies were produced. In order to produce chimeric antibodies, it is necessary to construct DNA encoding L ⁇ and H ⁇ of chimeric antibodies. The basic method for constructing both DNAs is as follows. The DNA sequences of the mouse leader sequence and mouse V region sequence found in PCR-cloned cDNA are used in mammalian cell expression vectors. It is to ligate the human C region that already exists in the DNA sequence to the coding sequence.
- the human antibody C region can be any human L chain C region and any human H chain C region.
- human L chain C or for C and H chain For IgG, Cr 1, C ⁇ 2, Cr 3 or Cr 4 (Ellison, J. et al., DNA, 1, 1 1 1 1 1 (1 8 1), Takahashi, N. , C e H, 29, 67 1-67 9 (198 2), K rawinke 1, U. et al., EMBOJ. 1, 40 3 — 40 7 (198 2)) or Each of the other ISO types can be mentioned.
- Two types of expression vectors are prepared for 'antibody production C', ie, under the control of an expression control region such as an enhancer / promoter system, a mouse L chain V region and a human L chain.
- the mouse H protein V region and the human H chain under the control of an expression vector consisting of DNA encoding the L protein C region and an expression control region such as the enhancer / promoter system.
- host cells such as mammalian cells are co-transformed with both of these expression vectors, and the transformed cells are cultured in vitro or in vivo to produce chimeric antibodies.
- W 091 — 1 692 8 for example, W 091 — 1 692 8).
- the DNA encoding the mouse L chain V region and human L chain C region and the DNA encoding the mouse H chain V region and human H chain C region are introduced into a single expression vector, Then, the vector can be used to transform a host cell, and the transformed cell can be cultured at an in-vivo or in-vivo to produce a chimeric antibody.
- Mouse WS — 4 Clones cDNA encoding the ⁇ -type L chain leader region and V region, cloned using PCR, and has a human genomic DNA encoding the human L protein C region. Link to an expression vector. Similarly, cDNA coding for the H-leader region and V-region of the mouse WS-4 antibody is cloned by PCR using the PCR method, and expression is performed with genomic DNA coding for the human] region. Link to vector.
- cDNAs encoding the V region of the mouse WS-4 antibody were introduced with appropriate nucleotide sequences at their 5 'and 3' ends ( 1) They must be expressed As is click data one easily inserts, and (2 ⁇ it we were in earthenware pots by function properly with said expression Beno 'in terpolymer (e.g., in the present invention and this for poison entering the K 0 zak sequence
- Beno 'in terpolymer e.g., in the present invention and this for poison entering the K 0 zak sequence
- the DNA encoding the V region of the mouse WS-4 antibody obtained by amplifying the primers by PCR using these primers was inserted into the desired DNA.
- the chimera WS-4 antibody When the binding activity of the chimera WS-4 antibody thus prepared was tested, the chimera WS-4 antibody showed an activity of binding to human IL-8 (see Fig. 2). Therefore, it was shown that the correct mouse V region was cloned and the sequence was correctly determined.
- the amino acid sequence of the FR of the mouse monoclonal antibody having the CDR to be transplanted must be prepared. It is desirable that there be high identity between the amino acid sequence of FR and that of the human monoclonal antibody to which the CDR is to be transplanted.
- the L-chain V region of the mouse WS-4 antibody was compared to the known L-chain V region of a human antibody by comparison with the human antibody HAU (Watanabe, S. et al., Hoppe—Seel's Z. 365, 1291-129, 970), which is most similar to the L ⁇ V region, with 69.2% identity.
- the H chain V region of the WS-4 antibody was compared with the known human antibody H chain V region in comparison with the human antibody VDH26 (Bu1 uwe 1a., L. et al., EMBOJ., 7, It is most similar to 200-3-210, 198 88) with 71.4% identity.
- the identity of the amino acid sequence of the mouse V region to the amino acid sequence of the human V region is lower than the identity of the amino acid sequence of the mouse V region to the amino acid sequence.
- the FR of the L ⁇ V region of the mouse WS-4 antibody is most similar to the consensus sequence of the FR of human L chain V region subgroup I (HSG1), with 64.4% identity. Exists.
- the FR of the H ⁇ V region of mouse WS-4 is most similar to the consensus sequence of the FR of subgroove 'III (HSGIII) of the human HII V region, with 62.3% of the same. Oneness exists.
- the L ⁇ V region in the human antibody HAU belongs to subgroup I of the human light chain V region.
- the H chain V region in the human antibody VDH26 belongs to subgroup III of the human H chain V region.
- a human L ⁇ V region belonging to subgroup I HSGI
- the reshaped human WS-4 antibody H chain V region was used. It is best to use the human antibody H chain V region belonging to subgroup ⁇ (HSG III) for the design of DNA.
- the L ⁇ V region of the mouse WS-4 antibody is the L ⁇ V of human anti-resting REI, which is a member of the subgroup 'I of the human L chain V region.
- the area was similar. Therefore, the FRs from RE RE were used in the design of the reshaped human WS-4 antibody.
- the original human REI Pa 1 n .: W c ;,. Hope-S e 1 er '? Z. P hysio '. Chem., 35 6, 16 7-19 1, 19 7 5; Ep P, 0. et al., Biochemistry, 14, 4 9 4 3-49
- 5 amino acids positions 39, 71, 104, 105 and 107; see Table 2 compared to 52,1975).
- the amino acid numbers in the table are based on the experience of Kabat, EA, et al. (1991).
- the change in the two amino acids at positions 39 and 71 was a change back to the amino acids present in the FRs of the L region V region of the rat CAMPATH-1H antibody (Riechmann et al.). , 198 8).
- three amino acid changes in FR4 were not found in other human eL proteins. It does not deviate from the human because it is based on the J region.
- RVLa the FR is identical to the REI-based FR present in the reconstituted human CAMPATH-1H antibody (Riechmann et al., 1988), and the CDR is the mouse WS It was identical to the CDR in the V region of the L chain of the 14 antibody.
- RVLb is based on RVLa and differs only in one amino acid at position 71 in human FR3. As defined by C hothia, C. et al., J. Mo 1. Biol. 196: 91-91, 19787, residue 71 is located in the L ⁇ V region. It is part of the standard (canonica 1) structure of CDR 1.
- the amino acid at this position is expected to directly affect the structure of the CDR1 loop of the V region of the L chain, and is therefore thought to greatly affect antibody binding.
- RVLb of the reshaped human WS-4 antibody L chain V region phenylalanine at position 71 has been changed to tyrosine.
- table 2 is the LmV region of the mouse WS-4 antibody.
- FR of REI modified for use in the CAPATH-1H antibody (Riechmann et al., 1988)
- the amino acid sequence of each of the two versions of the L ⁇ V region of the antibody WS-4 antibody is shown.
- REI FR is found in the reshaped human CAMPATH — 1H antibody (Riechmann et al., 1988).
- the five underlined amino acids in the FR of RE 1 are the amino acid residues of human REI.
- the amino acid is different from that in the column:
- the maleic acid is represented by one letter and the amino acid number is as defined by Kabat et al.
- the F R in the H chain V region of the mouse WS-4 antibody is most similar to the human H chain V region belonging to subgroove 111 (Table 1).
- the H $ V region of the mouse WS-4 antibody is one member of the subgroup ⁇ of the human H ⁇ V region, FR1 through FR3, compared to the known human H ⁇ V region. It was most similar to the H-domain V region of certain human antibody VDH26 (Bu1 uwe 1a, L. et al., EMBOJ., 7, 2003-302, 1098, 1988). . Regarding FR4, since the sequence of the FR of VDH26 has not been clarified, the human antibody 4 ⁇ ⁇ ⁇ 4 belonging to subgroup III (Sa ⁇ , I. et al., J. Immunol 1., 14 The amino acid sequence of FR4 of 2, 883-887, 1989) was used. These human H domain V regions were used as a basis for the design of the H ⁇ V region of the reconstituted human WS-4 antibody.
- Tables 3 and 4 show the H chain V region of mouse WS-4 antibody, FRs 1-3 of long-lived human antibody VDH26, FR4 of human antibody 4-4, and reconstituted human WS. — 4 The amino acid sequence of each of the eight versions of the V region of the ⁇ chain of the antibody. Table 3 Reconstruction hit WS — 4 H
- V region design (Continued in Table 4
- RVHa ⁇ h EVQ then ESGGG then VQPGGStR then SCAASGFTFS DYYLS
- RVHa RLTISREDSKNTLYtQMSSLKTEDLAV'YYCAR ENYRYDVELAY RVHb
- RVHa [! Are RVHa, RVHb, RVHc,
- WS-4H WGQGTLVTVSA RVHd, RVHe, RVHf, RVHg and 4B4 WGQGTLVTVSS RVHh are shown.
- the amino acid number is Kabat
- DNA encoding the first version of each of the reshaped human WS-4 antibody L chain and H chain V regions was synthesized. Then, determine the sequence and re- Constituent human WS—4 It was confirmed that the whole DNA sequence of antibody “L” and the HV region “a” coded the correct amino acid sequence.
- Reconstituted human WS Sequence of the 4 antibody LHV region purge ion “a” is shown in SEQ ID NO: 62, and sequence of the reshaped human WS4 antibody H chain V region version “a” is shown in SEQ ID NO: 38.
- the DNA coding for the other version of the reshaped human WS-4 antibody V region was prepared using the published version of PCR-mutagenesis (Kammann, M. , 17, 54, 4, 1989) with a slight modification. As described in the design of the reshaped human WS-4 antibody V region, one additional version of the reshaped human WS-4 antibody light chain V region (version "b") was added.
- the DNA to be coded is prepared and reconstituted human WS—4 antibody H protein V region with seven additional versions (no, 'one' b ',' cj, ' d ",” ej, "f", rg "and” hj) were prepared.
- Reconstructed human WS-4 antibody H chain V region purge region "b” is shown in SEQ ID NO: 65 as SEQ ID NO: 65
- reshaped human WS-4 antibody H chain V region version "b" and "c” , "D”, “e”, “f”, “g”, and “h” are shown in SEQ ID NOs: 41, 4, 45, 48, 51, 54, and 55, respectively.
- Reconstructed human WS — 4 antibody V region D ⁇ ⁇ sequence of various versions The DNA encoding the reshaped human 4 antibody V region was subcloned into a mammalian cell expression vector already harboring the DNA encoding the human C region. I did. That is, the DNA coding for the reshaped human WS-4 antibody V ⁇ L region is coded into the DNA sequence coding for the human light chain C region, and the reshaped human WS-4 antibody H chain V region is coded. The DNA was ligated to each of the DNA sequences encoding the human C1 region.
- both reconstituted human antibodies (RV and a / RVH g and RVL b / RVH g) comprising the L version "a" and 2 are "b" and the H version "g" Showed the ability to bind to IL-18 at the same level as the Chimera WS-4 antibody.
- any expression system such as a eukaryotic cell, such as an animal cell, such as an established mammalian cell line, a filamentous fungal cell , And yeast cells, as well as prokaryotic cells, for example, bacterial cells, for example, E. coli cells and the like.
- a eukaryotic cell such as an animal cell, such as an established mammalian cell line, a filamentous fungal cell , And yeast cells, as well as prokaryotic cells, for example, bacterial cells, for example, E. coli cells and the like.
- the chimeric or reshaped antibodies of the present invention are expressed in mammalian cells, such as C0S cells or CHO cells.
- conventional promoters useful for expression in mammalian cells can be used.
- human's site megalovirus phase I humancytomegalovirusimmediateear 1; HCMV
- expression vectors having an HCMV promoter include HCMV-VH-HCrl, HCMV-VL-HC and the like, which are derived from PSV2neo (International Publication W092-1977 ⁇ ). 9).
- promoters for gene expression in mammalian cells include retroviruses, polymolyviruses, and adenoviruses.
- Virus promoters such as virus, Simian Winnores 40 (SV40), or human 'polypeptides * chains' geronguesion' factor A promoter derived from a mammalian cell such as let (HEF-1 ⁇ ) may be used.
- SV40 Simian Winnores 40
- the method of MulIigan, R.C. et al. (Nature, 277, 108—114, 19779) and HEF — 1 o
- Mizushima, S. et al. Nucleic A cids Res.
- HEF-1a promoter Another specific example of a promoter useful for the present invention is the HEF-1a promoter.
- Expression vectors having this promoter include HEF-VH-grl and HEF-VL-g (Fig. 1).
- DNA sequences derived from poliovirus, adenovirus, SV40, bovine papillomavirus (BPV), etc. can be used.
- aminodarcoside 3'-phosphotransferase or neo resistance gene aminodarcoside 3'-phosphotransferase or neo resistance gene, thymidine kinase (TK) gene, Escherichia coli It is possible to use the gene for di-n-guanine phosphoribosyltransferase (XGPRT) gene and dihydrofolate reductase (dfr) gene.
- the present invention firstly encodes the L-chain V region and H-chain V region of a mouse monoclonal antibody against human IL-8, and the DNA encoding the L-chain V region and the H-chain V region. Provide DNA to be loaded.
- These are human mouse chimeric antibodies against human IL-18 and One example of a monoclonal antibody useful for producing a constituent human antibody is WS-4.
- the L chain V region has, for example, the amino acid sequence shown in SEQ ID NO: 26, and the H chain V region has, for example, the amino acid sequence shown in SEQ ID NO: 27. These amino acid sequences are coded by, for example, the nucleotide sequences shown in SEQ ID NOs: 26 and 27, respectively.
- the mouse L chain V region and mouse H chain V region and the DNA encoding them are as described above.
- the human L ⁇ C region can be any human light chain C region, such as a human C ⁇ or C region.
- the human H chain C region can be any human H chain C region and can be, for example, a human Crl, Cr2, Cr3 or Cr4 region (Ellison, J. et al. DNA, 1, 1 1 — 1 8 (1 9 8 1), Takahashi, N. et al., CeH, 29, 6 7 1-6 7 9 (1 9 8 2), K rawinke 1, U et al. , EMBOJ., 1, 4 0 3 — 4 0 7 (1 98 2)).
- a mouse LV region and a human L region C region under the control of an expression control region such as an enhancer promoter system.
- Expression vector containing DNA, and expression containing DNA encoding mouse H protein V region and human H ⁇ C region based on expression control region such as enhancer / promoter system make a vector.
- a host cell such as a mammalian cell, is co-transformed with these expression vectors, and the transformed cells are transformed in vitro or in vivo.
- quinora antibodies are coded: a mouse LV region and a human L region C region under the control of an expression control region such as an enhancer promoter system.
- the DNA encoding the mouse L chain V nod region and the human L chain C region, and the DNA encoding the mouse H chain V region and the human H chain C region are introduced into a single expression vector. Then, a host cell is transformed using the vector, and the transformed host is cultured in vivo or in vitro to produce the desired chimeric antibody. .
- the reshaped human W S-4 antibody of the present invention comprises:
- H ⁇ comprising a human H ⁇ FR and an H chain V region comprising the H chain CDR of a mouse monoclonal antibody WS-4 against human IL-8;
- the L chain CDR is the amino acid sequence shown in SEQ ID NO: 26, and the range of the amino acid sequence is defined in Table 5.
- the H chain CDR has an amino acid sequence represented by SEQ ID NO: 27, and the range of the amino acid sequence is defined in Table 5.
- the human L chain FR is derived from REI; the human H ⁇ FRs 1, 2 and 3 are derived from VDH26 and FR4 is derived from 4B4;
- the chain C region is a human C region; and the human H region C region is a human C7.1 region.
- the human HC region may be a human C74 region, or a radioisotope may be substituted for the human light chain C region and the Z or human HiC region. They may be combined.
- the L chain V region has the amino acid sequence shown as RVLa or RVLb in Table 2, and the H chain V region is shown in Tables 3 and 4 as RVHa, RVH. b, RVHc, RVHd, RVHe, RVHf, RVHg, or RVHh.
- the amino acid at position 41 in the H chain V region FR2 is proline and the amino acid at position 47 is tributphan And / or the amino acid at position 67 in FR 3 is preferably phenylalanine, and RVH b, RVH d, RVH e, RVH f, RVH g or RVH h Those having an amino acid sequence represented by are more preferable. Of these, RVHg is most preferred as the H ⁇ V region.
- reconstituted antibodies For the production of reconstituted antibodies, two types of expression vectors, DNA encoding the reconstituted human light chain as defined above under the control of an expression control region such as an enhancer / promoter system, are used.
- An expression vector comprising an expression vector comprising a reshaped human H-encoding DNA as defined above under an expression control region, such as an enhancer promoter system. I do.
- host cells such as mammalian cells, are co-transformed with these expression vectors, and the transformed cells are cultured in vivo or in vitro for reconstitution. To produce antibodies.
- the DNA encoding the reconstituted human L protein and the DNA encoding the reconstituted human H protein are introduced into a single expression vector, and the host is transformed using this vector. Then, the transformed host cells are cultured in vivo or in vitro to obtain the desired reconstituted human cells. To produce antibodies.
- the chimeric antibody or reshaped human antibody produced in this way can be used in a conventional manner, for example, for protein A-affinity chromatography or ion-exchange chromatography. It can be isolated and purified by chromatography, gel filtration, etc.
- the chimeric L protein or reconstituted human L protein of the present invention can be used to produce a complete antibody by combining it with an H chain.
- the chimeric H chain or reconstituted human H chain of the present invention can be used to produce a complete antibody by combining it with an L chain.
- the mouse L chain V region, the reconstituted human L chain V region, the mouse H chain V region, and the reconstituted human H protein V region of the present invention naturally bind to the antigen, human IL-18. It is considered to be useful as a medicine, a diagnostic agent, or the like as a region itself or as a fusion protein with another protein.
- L chain V region CDR and H chain V region CDR of the present invention are originally a portion that binds to the antigen, human IL-18, and may be used as such or as a fusion protein with another protein.
- pharmaceutical is considered to be useful as a diagnostic agent, such as ⁇ Te
- the DNA encoding the mouse L ⁇ V region of the present invention is useful for the production of DNA encoding chimeric L protein or DNA encoding reconstituted human L ⁇ .
- DNA encoding a mouse V chain V region is useful for producing DNA encoding a chimera chain or DNA encoding a reconstituted human.
- the DNA encoding the L chain V region CDR of the present invention is useful for the production of DNA encoding the reshaped human L chain V region and DNA encoding the reshaped human L chain.
- the DNA encoding the H ⁇ V region CDR of the present invention is useful for preparing DNA encoding the reshaped human H chain V region and DNA encoding the reshaped human H chain.
- the F ( ab ') z It is possible to produce a single-chain Fv in which F ab or F v is linked to both H straight and L f Fv in an appropriate host, and use it for the aforementioned purpose. (See, for example, Bird, RE, et al., TIBTECH, 9, 1332—137, 1991).
- Single-chain FV is obtained by linking the V region of the reshaped human antibody to human IL-8 and the V region of the light chain.
- the ⁇ ⁇ V region and the L ⁇ V region are linked via a linker, preferably a peptide linker (Huston, J.S. et al. Proc.Nal.A cad.S ci.U.S.A., 85,587 79-58 883,1988).
- the HIV region and L region V region in singleglutinin Fv may be any of those described above as the H chain and L region V region of the reconstituted human antigen.
- an H protein V region consisting of the amino acid sequence described in any of SEQ ID NOs: 38, 41, 44, 45, 48, 51, 54, 55
- a single chain FV comprising an L ⁇ V region consisting of the amino acid sequence of any of SEQ ID NOs: 62 and 65 (see W088-01649). ).
- V regions are preferably linked by a peptide linker.
- a peptide linker for example, any single peptide consisting of amino acid residues 12 to 19 is used (see W088-009344).
- the DNA coding for single-glutinin FV may be the DNA coding for the H region or V region of the reshaped human antibody described above and the DNA coding for the L chain or L chain V region.
- Type III the DNA portion encoding the desired amino acid sequence of those sequences is amplified by PCR using primer pairs defining both ends, and then, DNA encoding a portion of the peptide linker and both It is obtained by combining and amplifying a pair of primers that define the ends to be connected to each of the H and L ⁇ .
- DNAs encoding singleglutinin FV are prepared, an expression vector containing them and a host transformed with the expression vector can be obtained according to a conventional method.
- single tuin Fv can be obtained using the host according to a conventional method.
- Single-tuin FV is more easily transferred to tissues than antibody molecules, and is used for imaging by radioisotope labeling, and is a therapeutic agent that has the same function as reconstituted human antibodies. Is expected to be used.
- reshaped human antibodies to human IL-18 of the present invention As a method for confirming the binding activity of chimeric antibodies, reshaped human antibodies to human IL-18 of the present invention and their F (ab ') z , Fab, Fv or single chain FV, , ELISA (enzyme-linked immunosorbent assay), E1A (enzyme-linked immunosorbent assay), RIA (radioimmunoassay) or a fluorescent antibody method.
- an enzyme immunoassay is used for chimeric and reconstituted human antibodies
- human IL-8 is added to a plate coated with an anti-human IL-18 monoclonal antibody.
- a chimeric antibody against human IL-18 a culture supernatant of a cell producing a reconstituted human antibody or a purified sample is added thereto, and the mixture is labeled with an enzyme such as an alkaline phosphatase. Add the next antibody. After incubation and washing of the plate, the antigen binding activity can be evaluated by adding an enzyme substrate such as p-2-trophenyl phosphate and measuring the absorbance.
- a solution containing IL-18 appropriately labeled with Z5I and the like and unlabeled IL-8 is mixed with a solution containing the antibody of the present invention or a fragment thereof prepared at an appropriate concentration, and then mixed with the above solution. Add to neutrophil suspension. After a certain period of time, neutrophils can be separated and labeled activity on neutrophils can be measured.
- the antibody of the present invention or a fragment thereof is diluted with an appropriate culture solution, IL-8 is added, and the resultant is dispensed into a chamber. Then, the prepared neutrophil suspension is added to the chamber and left for a certain period of time.
- the migrating neutrophils adhere to the filter attached to the chamber, and the number of neutrophils may be measured by a usual method such as a staining solution or a fluorescent antibody. It is also possible to make judgments with the naked eye under a microscope or perform automatic measurement using a machine.
- the chimeric antibody against human IL-18 of the present invention, the reshaped human antibody, and the F (ab ') 2 , Fab, Fv or single chain FV thereof can be filtered through a membrane filter.
- a membrane filter After sterilization, preferably parenterally, for example, by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, etc., or by airway, for example, nebulizer ] I7.
- the dose to humans that can be administered as a pharmaceutical therapy varies depending on the condition and age of the patient, but is approximately 1 to 1000 mgZbody. O mgZkgZ Allows you to select a weekly divided dose.
- injectable preparations may include purified chimeric antibodies against human IL-8, reconstituted human antibodies and their F (ab ') 2 , Fab, Fv or single tune Fv in a solvent, e.g. It is dissolved in saline solution, buffer solution, etc. and added with an anti-adsorption agent, such as Tween 80, gelatin, human serum albumin (HSA), or for reconstitution before use. It may be freeze-dried. Sugar alcohols or sugars such as mannitol and glucose can be used as excipients for freeze-drying.
- the DNA encoding the variable region of the mouse monoclonal antibody against human IL-18 was cloned as follows.
- RNAs from the noibri dorma WS-4 were compared to Chirgwin, J. M. et al., Biochemistry, 18, 5 29 4-5 2 9 9,7,797, was prepared by modification of the method of density gradient centrifugation of heptachloride: ''' ⁇ ⁇ ⁇ .
- RNA pellet is washed with 80% ethanol, and 20 mM with 1 O mM EDTA and 0.5% N- sodium sodium lauroyl sarcosinate After dissolving Tris-HC 1 ( PH 7.5) 2 0 0 // 1 ⁇ , and adding Protenase (manufactured by Boehringer) to 0.5 mg ⁇ 1, The plate was incubated in a warm bath for 30 minutes at 37 ° C. The mixture was extracted with phenol and black-mouthed form, and the RNA was precipitated with ethanol. Next, the RN ⁇ precipitate was dissolved in 10 mM Tris-HC 1 (pH 7.5) 200 1 containing I mM EDTA.
- single-stranded cDNA was synthesized from about 40 ng of the mRNA obtained in step 2 above, and H town V area C Amplification of D ⁇ A: This was used.
- a single-stranded cDNA was synthesized from about 10 ⁇ g of the total RNA.
- the primer for PCR is as shown in SEQ ID NO: 13 to 24.
- PCR solution 1001 contains 10 mM Tris-HC1 (pH 8.3), 50 mM KC1, 0.ImM dNTPs (dATP, dGTP, dCTP.dTTP), 1. 5 mM M g C 1 2 , 0.
- MKC M0 use K appa
- SEQ ID NO: 12 C c ⁇ z ⁇ an ⁇ ⁇ ⁇ J J J '''J J J J J J J J (J one'.
- Amplification of cDNA was performed using the H chain in 4. (1) except that amplification was performed using a 0.25 / M MKV primer mixture and a 3.0 M MKC primer, respectively. Amplification was performed from 2.0 ⁇ l of the single ic DN'A solution obtained in 3. above in the same manner as described for the amplification of the V region gene.
- the D ⁇ fragments of each of the ⁇ chain V region and the L chain V region amplified by the PCR method as described above were separated by agarose gel electrophoresis using 1.5% low melting point agarose (manufactured by Sigma). A piece of agarose containing the approximately 450 bp long H fragment DNA fragment and the approximately 400 bp long L fragment DNA fragment was cut out, and then melted at 65 ° C. for 5 minutes. the HC 1 (P H 7 5.
- a DNA fragment comprising a gene encoding the mouse A: type L chain V region and a DNA fragment comprising the gene encoding the mouse H ⁇ V region were obtained.
- Each of the above DNA fragments has a S a1I cohesive end at its 5 ′ end and an XmaI cohesive end at its 3 ′ end.
- Sa1I-XmaI DNA fragment containing the gene coding for the mouse-Skappa-type L protein V region prepared as described above was used to prepare Sa1I, Xma PUC19 vector (Takara Shuzo) prepared by digesting with I and E. coli-derived alkaline phosphatase (BAP; Takara Shuzo) About 0.1 l / g, 1 unit In a reaction mixture containing T4 DNA ligase (GIBCO BRL) and the attached buffer, the reaction was carried out at 16 for 4 hours and ligated.
- GIBCO BRL T4 DNA ligase
- Escherichia coli was spread on the Old Spring Harbor Laboratory Press (19989), AL aboratory Manual, Sambrook et al., And incubated overnight at 37. Thus, an E. coli transformant was obtained.
- the transformant was cultured overnight in 37 ml of 2 XYT medium containing 50 g Zml of ambicilin at 37 ° C., and the culture was purified from a QIAGEN plasmid minikit (QIAGEN). Was prepared according to the method described in the instruction manual.
- pUC-WS41-VL The thus obtained plasmid having a gene encoding the mouse ⁇ -type L chain V region derived from the wild hybridoma WS-4 was named pUC-WS41-VL.
- a gene encoding a mouse H chain V region derived from hybridoma WS-4 is prepared according to the same method as described above, except that E. coli concomitant cells are used with JM109. Plasmids were made from the Sa1I-XmaI DNA fragment and named PUC-WS4-VH.
- the nucleotide sequence of the cDNA coding region in the above-mentioned plasmid was used as a sequence primer for M13PrimerRV and M13.
- SEQ ID NO: 26 shows the nucleotide sequence of the gene encoding the L region V region of the mouse WS-4 antibody, which is located at plasmid P ⁇ C—WS4—VL.
- SEQ ID NO: 27 shows the nucleotide sequence of a gene encoding the mouse V-region of the mouse WS-4 antibody contained in the plasmid PUC-WS4-V.
- the basic structures of the V regions of the L and ⁇ chains are similar to each other, with each of the four framework regions being linked by three hypervariable regions, the complementarity determining regions (CDRs).
- CDRs complementarity determining regions
- the amino acid sequence of the framework is relatively well conserved, while the amino acid sequence in the CDR region is extremely variable (Kabat, EA, et al. equencesof Proteinsof Immuno 1 ogica 1 Interest ”USD ept. Hea 1 thand Human Services, 1991).
- the amino acid sequence of the variable region of the mouse monoclonal antibody against human IL-18 was applied to the amino acid sequence database of the antibody created by Kabat et al. By examining the homology, the CDR region was determined as shown in Table 5.
- mouse WS — 4 cDNA clones encoding the L chain and H chain V regions, respectively p UC — WS 4 — VL and pUC—WS4—VH was modified by PCR. Then, it was introduced into a HEF expression vector (see W092—19759 and FIG. 1 described above).
- the posterior primer for the L chain V region (SEQ ID NO: 28) and the posterior primer for the H chain V region (SEQ ID NO: 29) are the leaders of each V region. Hybridizes to the coding DNA at the beginning of a sequence and provides a Kozak consensus system! (Kozak, M. et al., J. Uo1. Biol. 196, 947-950, 1987) and were designed to have a HindllI restriction site.
- the forward primer for the light chain V region (SEQ ID NO: 30) and the forward primer for the H chain V region (SEQ ID NO: 31) are the DNA sequences encoding the ends of the J region. And designed to add a subsequence donor sequence and a BamHI restriction site.
- the expression vectors were tested in COS cells to observe the transient expression of the Chimera WS-4 antibody.
- Each DNA (1 0 // g) was added to ⁇ Li co over bets 0. 8 ml of 1 X 1 0 7 cells Zml in PBS, to pulses of 1. Of 5 k V, 2 5 ⁇ F capacitor Gave.
- the electroporated cells were transferred to a DMEM culture medium (GIBC) containing 5% r-globulin free fetal serum. It was rinsed to 15 ml and added to tissue culture dishes. After incubation for 96 hours, culture supernatants were collected, cell debris was removed by centrifugation, and a disk final letter with a diameter of 0.45 // m (Ge 1 man S cience).
- GIBC DMEM culture medium
- ELISA plates for antigen binding measurement and antibody concentration measurement were prepared as follows.
- An ELISA plate for measuring the antigen binding activity was prepared as follows. 9
- Each plate of a 6-well plate (manufactured by Nunc) was solidified into a buffer (0.1 M) at a concentration of 2 g Zm 1.
- TAGO Ze-labeled goat anti-human IgG antibody
- 96-well plate was solidified with 1 tig / m 1 goat anti-human IgG antibody (manufactured by TAGO) 100 I, and after blocking, Purified chimera antibody samples or culture supernatants of COS cells expressing them were serially diluted and added to each well, and then concentrated at a concentration of 11 mM alkaline phosphatase-conjugated goat antibody.
- -Human IgG antibody (TAGO) 100a1 was added. After incubation and washing, a substrate solution (1 mg / m1P—nitrofuunil phosphoric acid, manufactured by Sigma) was added, and then the absorbance at 405 ⁇ was measured.
- the DNA coding for the reshaped human WS-4 antibody H V region was designed as follows. Known DNA sequences encoding FR1 to 3 of human antibody VDH26 and FR4 of human antibody 4B4 are ligated to DNA sequences encoding CDRs of mouse WS-4 antibody H chain V region. Thus, a full-length DNA encoding the reshaped human WS-4 antibody H protein V region was designed.
- a HindII I recognition site / K0ZAK consensus sequence and a BamHI recognition site / splice donor sequence were added to the 5 'and 3' sides of this DNA sequence, respectively, and HEF was added. Insertion into the expression vector was enabled.
- the DNA sequence thus designed is divided into four approximately equal oligonucleotides, which in turn may interfere with the assembly of these oligonucleotides.
- the secondary structure in the oligonucleotide was analyzed by a computer.
- the sequences of the four oligonucleotides are shown in SEQ ID NOs: 32 to 35. These oligonucleotides have a length of 113 to 144 bases, and two adjacent oligonucleotides have a 20-base homologous region with each other. Of the four oligonucleotides, HF 1 (SEQ ID NO: 32) and HF 3 (SEQ ID NO: 34) have a sense DNA sequence, And another HF? (K column number: 3?), HF.! (SEQ ID NO: 35 has an antisense DNII sequence. These oligonucleotides can be converted to an automatic DNA synthesizer (App 1 ied Biosystems). ).
- Fig. 3 shows a method of assembling these four oligonucleotides by PCR. Approximately 10 ng of HF1 and HF2, and HF3 and HF4 were combined and added to a final reaction volume of 98 ⁇ l containing 2.5 u of Pfu DNA polymerase. . After the initial denaturation at 9 4 for 3 minutes, one cycle of 9 4 for 2 minutes, 5 5 for 2 minutes and 7 2 for 2 minutes is performed for 2 cycles. C
- the PCR reaction mixture was added. With 50; 1 mineral oil and a first denaturation at 94 ° C for 3 minutes, followed by 94 ° C for 1 minute, 55 ° (: 1 minute and 72 ° C). The cells were incubated for 45 minutes for 1 minute and then incubated for 10 minutes at 72.
- the DNA fragment of about 450 base pairs was purified using a 1.5% low melting point agarose gel and purified by H digested with indIll and BamHI and then cloned into the HEF expression vector HEF — VH — gr1 o EF — 1 primer (SEQ ID NO: 66) and HIP primer ( After determining the DNA sequence using SEQ ID NO: 67), the plasmid containing the DNA fragment encoding the correct amino acid sequence of the H region V region was named HEF-RVH a-gr1.
- SEQ ID NO: 38 shows the amino acid sequence and base sequence of the V region of the H chain contained in this plasmid HEF—RVHa- ⁇ 1.
- the reshaped human W5 antibody HV regions are identified as “b —. ⁇ -”, “D”, “e”, “ ⁇ ”, “g”, and “ ⁇ ” as follows. It was prepared as follows.
- Version “b” is a mutagenic primer, LTW1 (SEQ ID NO: 39), designed to mutate strongly into a tributin phantom at position 47.
- LTW-2 SEQ ID NO: 40
- RVH 5 '(SEQ ID NO: 36) and RVH 3' SEQ ID NO: 37
- Mid HEF — RVH a — grl was used as type I DNA and amplified by PCR to obtain plasmid HEF — RVH b — gr 1.
- the amino acid sequence and the base sequence of the H chain V region contained in this plasmid HEF—RVHb-gr1 are shown in SEQ ID NO: 41.
- Version “c” refers to the mutagenic primers QTP1 (SEQ ID NO: 42) and QTP2 (SEQ ID NO: 4) designed to mutate 41-position glutamine to proline.
- plasmid 3 plasmid HEF — RVH — grl was used as type I DNA and amplified by PCR to obtain plasmid HEF — RVH c — gr1.
- the amino acid sequence and base sequence of the H ⁇ V region contained in this plasmid HEF—RVHc-gr1 are shown in SEQ ID NO: 44.
- Version ⁇ d uses QTP1 and QTP2 as mutagenic primers, uses plasmid HEF — RVH b-gr1 as type I DNA, and converts plasmid HEF — RVH d — gr1 into plasmid DNA. Obtained.
- the amino acid sequence and nucleotide sequence of the H region V region contained in this plasmid HEF-RVHd-grl are shown in SEQ ID NO: 45.
- Version “ej” was obtained by using mutagenic primers ATP1 (SEQ ID NO: 46) and ATP2 (SEQ ID NO: 47) designed to mutate alanine at position 40 to proline, Mid HEF — RVH d -g 7] was amplified on a proud DA and amplified to obtain -'- HEF-PVH-gr1.
- the amino acid sequence and base sequence of the H chain V region of this plasmid HEF-RVHe-1 are shown in SEQ ID NO:
- Version “ ⁇ ” is a mutagenic BRI GTA1 (SEQ ID NO: 49) and GTA2 (SEQ ID NO: 50) designed to mutate the glycin at position 44 to alanine. )
- GTA2 SEQ ID NO: 50
- Section “ g ” is a mutagenic primer designed to convert rouisin at position 67 to phenalanine LTF 1 (SEQ ID NO: 52) and LTF 2 Using (SEQ ID NO: 53), plasmid HEF—RVH d—gr1 was amplified as type I DNA to obtain plasmid HEF—RVH g-gr1.
- the amino acid sequence and base sequence of the V region of the H chain contained in the plasmid HEF-RVHg-1 are shown in SEQ ID NO:
- Version “h” uses LTF1 and LTF2 as mutagenic primers, amplifies brassmid HEF — RVH b-gr1 as type I DNA, HEF — RVH h — g r 1
- the amino acid sequence and base sequence of the H region V region in this plasmid HEF-RVHh-gr1 are shown in SEQ ID NO: 55.
- the DNA encoding the L chain V region of the reshaped human WS-4 antibody was designed as follows. DNA sequence encoding FR of human antibody REI and mouse WS — 4 DNA sequence encoding CDR of antibody L chain V region We designed a full-length DNA fragment that encodes the reconstituted human WS-4 antibody LIII.V region so as to be linked.
- a Hind111 recognition site / K0ZAK consensus sequence and a BamHI recognition site / subrice donor sequence were added to the 5 'and 3' sides of this DNA sequence, respectively, to express HEF. Enabled to be inserted into the vector.
- the DNA sequence thus designed is divided into four oligonucleotides of approximately equal length, and then the oligonucleotides that may interfere with the assembly of these oligonucleotides The structure of the secondary structure in the nucleoside was analyzed by a contributor.
- the sequences of the four oligonucleotides are shown in SEQ ID NOs: 56-59. These oligonucleotides have a length of 06 to 124 bases, and two adjacent oligonucleotides are 19 to 23 bases apart from each other. Having. Of the four oligonucleotides, LF1 (SEQ ID NO: 56) and LF3 (SEQ ID NO: 58) have a sense DNA sequence, and the other LF2 (SEQ ID NO: 58). 57) and LF4 (SEQ ID NO: 59) have antisense DNA sequences. These oligonucleotides were synthesized in the same manner as in HF 1-4 described above.
- the assembly was performed at 94'C with a PCR mix of 981 containing 4 OOng of each of the 4 oligonucleotides and 5u of Amp1iT aq. After an initial denaturation of 3 minutes, one cycle consisted of 94 minutes for 2 minutes, 55 minutes for 2 minutes, and 72 minutes for 3 minutes, and this was performed for 2 cycles. After adding the RVL 5 'primer (SEQ ID NO: 60) and RVL 3' primer (SEQ ID NO: 61) in lOO p moles as external primers, the PCR reaction mixture was added.
- a DNA fragment of about 400 base pairs was purified using a 1.5% low melting point agarose gel, digested with Hind III and Bam HI, and then the HEF expression vector HEF—VL—g Crowjung. After determining the DNA sequence using EF-1 primer (SEQ ID NO: 6G) and KIP primer (SEQ ID NO: 68), encode the correct amino acid sequence of the L chain V region.
- the plasmid containing the DNA fragment was named HEF-RVLa-g.
- the amino acid sequence and the base sequence of the V region of the ⁇ chain, which is included in this plasmid HEF—RVLa—g ⁇ , are shown in SEQ ID NO: 62.
- Version “b” is the mutagenic primer FTY1 (SEQ ID NO: 63) and FTY2 designed to mutate phenylalanine at position 71 to tyrosine. (SEQ ID NO: 64) and RVL 5 '(SEQ ID NO: 60) and RVL 3' (SEQ ID NO: 61) as primers for defining both ends.
- HEF — RVL a — gc was used as type I DNA and amplified by PCR to obtain plasmid HEF — RVL b —.
- the amino acid sequence and nucleotide sequence of the L region V region contained in this plasmid HE F — R V L b -g ⁇ are shown in SEQ ID NO: 65.
- the “a” version (RVLa) of the reshaped human WS-4 antibody L chain showed the same binding activity as the chimeric WS-4 antibody L chain.
- the “a” version (RVLa) of the reconstituted H fragment and reconstituted human WS—4 antibody L fragment were simultaneously transfected into COS cells. It was done by taking a shot.
- Antibodies with a version (RVH g) are capable of reforming functional antigen-binding sites with good antigen-binding properties and co-transfection into COS cells. Suggests that it produces a production level comparable to that of Mera WS-4 antibody (chL / chH) Done ⁇
- RVLa H chain “a” version
- RVH g H chain “g” version
- RVLb L chain “b” purge ion
- the above neutrophil suspension is centrifuged, and the cell concentration is 2X in the binding buffer (D-PBS containing 1% BSA and 0.1% sodium azide).
- CT / JP94Z080959 CT / JP94Z080959
- human IL-16 its antigen, human IL-16, were added at concentrations of about 50 / g Zml and about 40 ng / ml, respectively. For 30 minutes.
- IL-18 radiolabeled with 125 I (74 TB q / mmol. Amersham) and unlabeled IL-18 (Amersbam) was used.
- Two-fold serial dilutions were performed to about 8 ng / ml, with a mI force.
- the IL-18 solution and each antibody solution were mixed in 501 each, and incubated at ice temperature for 30 minutes. Thereafter, the neutrophil suspension 1001 was added, and the mixture was incubated at ice temperature for 1 hour while stirring every 15 minutes. After incubation, this cell suspension was overlaid on a 20% 20% saccharose solution, centrifuged and frozen. To measure the amount of IL-18 bound to the cells, the cell sediment was cut, and the radioactivity was measured using an r-counter (manufactured by Aroca). Figure 8 shows the results.
- RVLa L chain "a” version
- RVH g H chain “g” version
- RVLb L chain "b” purge ion
- Antibodies with the same H chain “g” version (RVH g) inhibit IL-8 binding to the IL-8 receptor to the same extent as chimeric antibodies (chL / chH) It was found to have activity.
- E. coli having the plasmid HEF-RVLa-g is Escherichiaco 1 i DH5 or (HEF-RVLa-gA :), and E. coli having the plasmid HEF-RVHg-gr1 is Escherichiacoli JM109 (HEF-RVH g-gr1) was submitted to the Institute of Biotechnology and Industrial Technology (I 1-3, Higashi 1-3-chome, Tsukuba-shi, Ibaraki Prefecture) by the Institute of Industrial Science and Technology. On that day, they were internationally deposited under the Budapest Treaty as FERMBP-47338 and FERMBP-4714, respectively.
- the hybridoma producing anti-human IL-8 monoclonal antibody was composed of spleen cells and mouse myeloma cells of BALB nc mice immunized with human IL-8, P3X63-Ag8.6. 53 was prepared by fusing polyethylene glycol in a conventional manner. Screening was performed using the activity of binding to human IL-8 as an indicator, and hybridoma WS-4 was established (Ko, ⁇ -C., Et al., J. Immunol. Methods, 1). 4 9, 2 2 7-2 3 5, 1 9 9 2) ⁇ Industrial applicability
- the present invention provides a reshaped human antibody against human IL-8, in which the CDRs of the V region of the human antibody are replaced by CDRs of a mouse monoclonal antibody against human IL-8. .
- Most of the reshaped human antibodies are derived from human antibodies, and CDRs are originally low in antigenicity, so that the reshaped human antibodies of the present invention have low antigenicity to humans, and Therefore, it is expected to be used for medical therapy.
- Escherichia col i DH5 (HEF-R V then a-g A:)
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Organism name Mouse Immediate origin
- Sequence type nucleic acid
- ATC CAG TGT GAG GTG AAA CTG GTG GAG TCT GGA GGA GGC TTG ATA CAG 96 lie Gin Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Gly Leu He Gin
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- TAAGCTTCCA CCATGGAGTT TGGGCTGAGC TGGGTTTTCC TTGTTGCTAT TTTAAAGGGT 60 GTCCAGTGTG AAGTGCAGCT GTTGGAGTCT GGGGGAGGCT TGGTCCAGCC TGGGGGTTCT 120 CTGAGACTCT CATGTGC 137 SEQ ID NO: 3 3
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid Number of towns: One town
- Sequence type nucleic acid
- Organism name mouse and human
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Organism name mouse and human Immediate origin
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Organism name mouse and human
- Organism name mouse and human
- Sequence type nucleic acid
- Sequence type nucleic acid
- Sequence type nucleic acid
- Organism name mouse and human
- Amino acid 1 0 1-1 1 1 CDR 3
- Amino acid 1 1 2 — 1 2 2 FR 4 sequence
- Sequence type nucleic acid
- Sequence type nucleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69535243T DE69535243T2 (de) | 1994-07-13 | 1995-07-12 | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
HU9700093A HU221385B1 (en) | 1994-07-13 | 1995-07-12 | Reconstituted human antibody against human interleukin-8 |
EP95925116A EP0770628B9 (en) | 1994-07-13 | 1995-07-12 | Reconstituted human antibody against human interleukin-8 |
AU29363/95A AU701342B2 (en) | 1994-07-13 | 1995-07-12 | Reconstituted human antibody against human interleukin-8 |
KR1019970700191A KR100261941B1 (ko) | 1994-07-13 | 1995-07-12 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
US08/765,783 US5994524A (en) | 1994-07-13 | 1995-07-12 | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
US09/416,557 US6245894B1 (en) | 1994-07-13 | 1999-10-12 | Reshaped human antibody to human interleukin-8 |
US09/730,857 US20020082396A1 (en) | 1994-07-13 | 2000-12-07 | Reshaped human antibody to human interleukin-8 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/161481 | 1994-07-13 | ||
JP16148194 | 1994-07-13 | ||
JP6/289951 | 1994-11-24 | ||
JP28995194 | 1994-11-24 | ||
JP31078594 | 1994-12-14 | ||
JP6/310785 | 1994-12-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/765,783 Continuation US5994524A (en) | 1994-07-13 | 1995-07-12 | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996002576A1 true WO1996002576A1 (fr) | 1996-02-01 |
Family
ID=27321865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/001396 WO1996002576A1 (fr) | 1994-07-13 | 1995-07-12 | Anticorps humain reconstitue contre l'interleukine-8 humaine |
Country Status (10)
Country | Link |
---|---|
US (3) | US5994524A (ja) |
EP (1) | EP0770628B9 (ja) |
KR (1) | KR100261941B1 (ja) |
AT (1) | ATE340590T1 (ja) |
AU (1) | AU701342B2 (ja) |
CA (1) | CA2194907A1 (ja) |
DE (1) | DE69535243T2 (ja) |
HU (1) | HU221385B1 (ja) |
WO (1) | WO1996002576A1 (ja) |
ZA (1) | ZA955832B (ja) |
Cited By (327)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040215A1 (fr) * | 1996-04-23 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Medicament contre l'infarctus du myocarde contenant comme principe actif un anticorps anti-il-8 |
WO1997039772A1 (fr) * | 1996-04-19 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif |
US5702946A (en) * | 1994-03-03 | 1997-12-30 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders |
WO1997049426A1 (fr) * | 1996-06-26 | 1997-12-31 | Chugai Seiyaku Kabushiki Kaisha | Medicaments destines aux lesions pulmonaires aigues dues a des causes indirectes, contenant un anticorps anti-il-8 comme principe actif |
WO1998017312A1 (fr) * | 1996-10-22 | 1998-04-30 | Chugai Seiyaku Kabushiki Kaisha | Remede contre les troubles septiques et comprenant un anticorps anti-il-8 en qualite d'ingredient actif |
WO1998024884A1 (en) * | 1996-12-02 | 1998-06-11 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies |
WO1999018997A1 (fr) | 1997-10-14 | 1999-04-22 | Chugai Seiyaku Kabushiki Kaisha | Potentialisateur pour anticorps anti-tumeur lymphoide |
US6025158A (en) * | 1997-02-21 | 2000-02-15 | Genentech, Inc. | Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
WO2002052008A1 (fr) | 2000-12-22 | 2002-07-04 | Kazusa Dna Research Institute Foundation | Nouveaux genes associes au cancer |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
WO2003068259A1 (en) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
WO2004019966A1 (ja) | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
WO2005014818A1 (ja) | 2003-08-08 | 2005-02-17 | Perseus Proteomics Inc. | 癌高発現遺伝子 |
US6870033B1 (en) | 1997-02-21 | 2005-03-22 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
WO2005007800A3 (ja) * | 2003-07-18 | 2005-03-31 | Mochida Pharm Co Ltd | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
WO2005035754A1 (ja) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
WO2006132363A1 (ja) | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
WO2007046439A1 (ja) | 2005-10-18 | 2007-04-26 | National Institute Of Agrobiological Sciences | 抗体を産生するトランスジェニックカイコとその製造方法 |
US7214776B2 (en) | 1999-01-21 | 2007-05-08 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
WO2007114325A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
US7282568B2 (en) | 2002-12-16 | 2007-10-16 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
EP1849479A1 (en) | 2000-08-16 | 2007-10-31 | Chugai Seiyaku Kabushiki Kaisha | Ameliorating agent for symptoms resulting from joint diseases |
EP1854481A2 (en) | 1996-04-23 | 2007-11-14 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient |
WO2007129457A1 (ja) | 2006-04-25 | 2007-11-15 | The University Of Tokyo | アルツハイマー病および癌の治療薬 |
WO2007142325A1 (ja) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | 炎症性疾患の予防または治療剤 |
WO2007145227A1 (ja) | 2006-06-14 | 2007-12-21 | Chugai Seiyaku Kabushiki Kaisha | 造血幹細胞増加促進剤 |
WO2007148417A1 (en) | 2006-06-21 | 2007-12-27 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to fzd10 and uses thereof |
WO2008007755A1 (fr) | 2006-07-13 | 2008-01-17 | Chugai Seiyaku Kabushiki Kaisha | inducteur de mort cellulaire |
WO2008010556A1 (fr) | 2006-07-21 | 2008-01-24 | Chugai Seiyaku Kabushiki Kaisha | Médicament agissant contre une maladie rénale |
WO2008012049A1 (en) | 2006-07-24 | 2008-01-31 | Institut Pasteur | Post-translationally modified neurotrophins |
WO2008020586A1 (en) | 2006-08-14 | 2008-02-21 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
WO2008047914A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif |
WO2008047925A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif |
WO2008047723A1 (en) | 2006-10-12 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-ereg antibody |
WO2008072723A1 (ja) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断 |
WO2008081942A1 (ja) | 2007-01-05 | 2008-07-10 | The University Of Tokyo | 抗prg-3抗体を用いる癌の診断および治療 |
WO2008093688A1 (ja) | 2007-01-30 | 2008-08-07 | Forerunner Pharma Research Co., Ltd. | キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法 |
WO2008105560A1 (ja) | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | 抗grp78抗体を有効成分として含む医薬組成物 |
WO2008111597A1 (ja) | 2007-03-12 | 2008-09-18 | Chugai Seiyaku Kabushiki Kaisha | Hlaクラスiを認識する抗体を有効成分として含有する化学療法剤耐性癌治療剤、およびその利用 |
EP1987842A1 (en) | 2000-04-28 | 2008-11-05 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitor |
WO2009001840A1 (ja) | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | ADCC活性又はCDC活性を有する抗Prominin-1抗体 |
EP2011514A1 (en) | 1997-03-21 | 2009-01-07 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
WO2009008414A1 (ja) | 2007-07-10 | 2009-01-15 | Shionogi & Co., Ltd. | Mmp13に対する中和活性を有するモノクローナル抗体 |
WO2009041062A1 (ja) | 2007-09-28 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 血漿中動態が改善されたグリピカン3抗体 |
WO2009051108A1 (ja) | 2007-10-15 | 2009-04-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
WO2009063970A1 (ja) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | 抗gpr49抗体を用いる癌の診断および治療 |
WO2009072598A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 掻痒症治療剤 |
WO2009072604A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 抗nr10抗体、およびその利用 |
EP2075257A1 (en) | 2002-09-04 | 2009-07-01 | Chugai Seiyaku Kabushiki Kaisha | Preparation of antibody using mrl/lpr mouse |
WO2009084659A1 (ja) | 2007-12-27 | 2009-07-09 | Chugai Seiyaku Kabushiki Kaisha | 高濃度抗体含有溶液製剤 |
WO2009087978A1 (ja) | 2008-01-11 | 2009-07-16 | The University Of Tokyo | 抗cldn6抗体 |
WO2009122667A1 (ja) | 2008-04-04 | 2009-10-08 | 中外製薬株式会社 | 肝癌治療剤 |
WO2009125825A1 (ja) | 2008-04-11 | 2009-10-15 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP2116261A1 (en) | 2008-05-07 | 2009-11-11 | Institut Pasteur | Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof |
WO2009147781A1 (ja) | 2008-06-02 | 2009-12-10 | 国立大学法人東京大学 | 抗がん剤 |
WO2010005068A1 (ja) | 2008-07-10 | 2010-01-14 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
WO2010016526A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
WO2010038610A1 (ja) | 2008-09-30 | 2010-04-08 | オリエンタル酵母工業株式会社 | 新しい軟骨細胞増殖及び分化誘導剤 |
WO2010040766A1 (en) | 2008-10-07 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
WO2010055950A1 (ja) | 2008-11-17 | 2010-05-20 | 財団法人ヒューマンサイエンス振興財団 | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
WO2010064697A1 (ja) | 2008-12-05 | 2010-06-10 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
WO2010073694A1 (ja) | 2008-12-25 | 2010-07-01 | 国立大学法人東京大学 | 抗tm4sf20抗体を用いた癌の診断と治療 |
WO2010074192A1 (ja) | 2008-12-26 | 2010-07-01 | 国立大学法人東京大学 | 抗lgr7抗体を用いる癌の診断および治療 |
WO2010074049A1 (ja) | 2008-12-22 | 2010-07-01 | 株式会社 未来創薬研究所 | 抗hs6st2抗体及びその用途 |
EP2208783A1 (en) | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
EP2216046A2 (en) | 2004-07-09 | 2010-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
EP2228445A1 (en) | 2003-06-18 | 2010-09-15 | Chugai Seiyaku Kabushiki Kaisha | Fucose Transporter |
WO2010106051A1 (en) | 2009-03-17 | 2010-09-23 | Universite De La Mediterranee | Btla antibodies and uses thereof |
WO2010113117A2 (en) | 2009-03-30 | 2010-10-07 | Edimer Biotech S.A. | Preparation of isolated agonist anti-edar monoclonal antibodies |
WO2010119691A1 (ja) | 2009-04-16 | 2010-10-21 | 国立大学法人東京大学 | 抗tmprss11e抗体を用いた癌の診断と治療 |
WO2010126137A1 (ja) | 2009-05-01 | 2010-11-04 | 国立大学法人 東京大学 | 抗カドヘリン抗体 |
WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
WO2010137654A1 (ja) | 2009-05-29 | 2010-12-02 | 株式会社未来創薬研究所 | Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
EP2261230A1 (en) | 2002-09-11 | 2010-12-15 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
US7875705B2 (en) | 2007-05-28 | 2011-01-25 | The University Of Tokyo | Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody |
WO2011021381A1 (ja) | 2009-08-17 | 2011-02-24 | 株式会社未来創薬研究所 | 抗hb-egf抗体を有効成分として含む医薬組成物 |
EP2289944A2 (en) | 2003-10-10 | 2011-03-02 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody substituting for functional proteins |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
WO2011037160A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | Hlaクラスiを認識する抗体 |
US7931897B2 (en) | 2001-02-07 | 2011-04-26 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for hematopoietic tumors |
WO2011057188A1 (en) | 2009-11-06 | 2011-05-12 | Idexx Laboratories, Inc. | Canine anti-cd20 antibodies |
WO2011090088A1 (ja) | 2010-01-20 | 2011-07-28 | 中外製薬株式会社 | 安定化抗体含有溶液製剤 |
EP2351483A1 (en) | 1999-10-01 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Prevention and treatment of blood coagulation-related diseases |
WO2011093097A1 (ja) | 2010-01-29 | 2011-08-04 | 株式会社未来創薬研究所 | 抗dll3抗体 |
WO2011092989A1 (ja) | 2010-01-29 | 2011-08-04 | 東レ株式会社 | ポリ乳酸系樹脂シート |
WO2011096528A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096534A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096519A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096517A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096533A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011099524A1 (ja) | 2010-02-10 | 2011-08-18 | 富士フイルムRiファーマ株式会社 | 放射性金属標識抗カドヘリン抗体 |
WO2011105573A1 (ja) | 2010-02-26 | 2011-09-01 | 株式会社未来創薬研究所 | 抗icam3抗体およびその用途 |
WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2011122011A2 (en) | 2010-03-30 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
WO2012005076A1 (ja) | 2010-07-08 | 2012-01-12 | 本田技研工業株式会社 | 高周波加熱用コイル |
WO2012010696A1 (en) | 2010-07-23 | 2012-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
WO2012043747A1 (ja) | 2010-09-30 | 2012-04-05 | 独立行政法人理化学研究所 | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 |
WO2012057328A1 (ja) | 2010-10-29 | 2012-05-03 | 株式会社ペルセウスプロテオミクス | 高い内在化能力を有する抗cdh3抗体 |
WO2012061120A1 (en) | 2010-10-25 | 2012-05-10 | Regents Of The University Of Minnesota | Therapeutic composition for treatment of glioblastoma |
WO2012067176A1 (ja) | 2010-11-17 | 2012-05-24 | 中外製薬株式会社 | 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子 |
WO2012073985A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
WO2012080351A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
WO2012085132A1 (en) | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
WO2012090939A1 (ja) | 2010-12-27 | 2012-07-05 | 国立大学法人名古屋大学 | 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法 |
WO2012093704A1 (ja) | 2011-01-07 | 2012-07-12 | 中外製薬株式会社 | 抗体の物性を改善させる方法 |
WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
WO2012107531A1 (en) | 2011-02-09 | 2012-08-16 | Ruprecht-Karls-Univeristät Heidelberg | B-type plexin antagonists and uses thereof |
WO2012115241A1 (ja) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | FcγRIIb特異的Fc抗体 |
WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
WO2012131004A2 (en) | 2011-03-31 | 2012-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
WO2012133914A1 (ja) | 2011-03-31 | 2012-10-04 | オリエンタル酵母工業株式会社 | Ranklアンタゴニストを含む癌免疫増強剤 |
US8287863B2 (en) | 1999-08-23 | 2012-10-16 | Chugai Seiyaku Kabushiki Kaisha | Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen |
WO2012144208A1 (ja) | 2011-04-18 | 2012-10-26 | 国立大学法人東京大学 | 抗itm2a抗体を用いる癌の診断および治療 |
WO2012156532A1 (en) | 2011-05-19 | 2012-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human-her3 antibodies and uses thereof |
WO2012175692A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
WO2012175691A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
EP2543679A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543678A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543677A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
WO2013017691A1 (en) | 2011-08-04 | 2013-02-07 | Medizinische Universität Innsbruck | Cahgt1p inhibitors for use in the treatment of candidiasis |
WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018889A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018883A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013017656A1 (en) | 2011-08-02 | 2013-02-07 | Medizinische Universität Wien | Antagonists of ribonucleases for treating obesity |
WO2013024517A1 (ja) | 2011-08-12 | 2013-02-21 | 国立感染症研究所 | アスペルギルス フミガーツス感染症の検査、予防及び治療のための方法並びに組成物 |
WO2013027802A1 (ja) | 2011-08-23 | 2013-02-28 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ddr1抗体 |
WO2013035824A1 (ja) | 2011-09-07 | 2013-03-14 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞の分離 |
WO2013046722A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | イオン濃度依存性結合分子ライブラリ |
WO2013047729A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 標的抗原に対する免疫応答を誘導する抗原結合分子 |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
WO2013047752A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 抗原の消失を促進する抗原結合分子 |
WO2013046704A2 (en) | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE |
WO2013051294A1 (ja) | 2011-10-05 | 2013-04-11 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
WO2013062083A1 (ja) | 2011-10-28 | 2013-05-02 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞特異的分子 |
WO2013065708A1 (ja) | 2011-10-31 | 2013-05-10 | 中外製薬株式会社 | 重鎖と軽鎖の会合が制御された抗原結合分子 |
WO2013081143A1 (ja) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬 |
WO2013100120A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤 |
WO2013106572A1 (en) | 2012-01-11 | 2013-07-18 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Bispecific antibody fragments for neurological disease proteins and methods of use |
WO2013118858A1 (ja) | 2012-02-09 | 2013-08-15 | 中外製薬株式会社 | 抗体のFc領域改変体 |
WO2013125630A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125636A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125640A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125654A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
WO2013147169A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び/又は予防用医薬組成物 |
WO2013147153A1 (ja) | 2012-03-29 | 2013-10-03 | 株式会社未来創薬研究所 | 抗lamp5抗体およびその利用 |
WO2013147176A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
WO2013150623A1 (ja) | 2012-04-04 | 2013-10-10 | 株式会社ペルセウスプロテオミクス | 抗cdh3(p-カドヘリン)抗体の薬剤コンジュゲート |
WO2013161814A1 (ja) | 2012-04-23 | 2013-10-31 | ジーンフロンティア株式会社 | 抗ヒトcd69抗体、及びその医薬用途 |
WO2013168820A1 (ja) | 2012-05-11 | 2013-11-14 | 公益財団法人微生物化学研究会 | 抗cxadr抗体 |
WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
WO2013180201A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 会合化した抗原を消失させる抗原結合分子 |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
WO2014001368A1 (en) | 2012-06-25 | 2014-01-03 | Orega Biotech | Il-17 antagonist antibodies |
WO2014021339A1 (ja) | 2012-07-30 | 2014-02-06 | 国立大学法人名古屋大学 | ヒトミッドカインに対するモノクローナル抗体 |
WO2014030728A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | FcγRIIb特異的Fc領域改変体 |
WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
WO2014033327A1 (en) | 2012-09-03 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos for treating graft-versus-host disease |
WO2014042251A1 (ja) | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
WO2014050926A1 (ja) | 2012-09-28 | 2014-04-03 | 中外製薬株式会社 | 血液凝固反応の評価方法 |
WO2014051022A1 (ja) | 2012-09-27 | 2014-04-03 | 中外製薬株式会社 | Fgfr3融合遺伝子およびそれを標的とする医薬 |
WO2014073292A1 (ja) | 2012-11-09 | 2014-05-15 | ジーンフロンティア株式会社 | 癌治療のための抗adam28抗体 |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
WO2014079886A1 (en) | 2012-11-20 | 2014-05-30 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
WO2014123227A1 (ja) | 2013-02-08 | 2014-08-14 | 株式会社医学生物学研究所 | ヒトnrg1タンパク質に対する抗体 |
WO2014126198A1 (ja) | 2013-02-15 | 2014-08-21 | 株式会社ペルセウスプロテオミクス | 抗cdh3ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用 |
WO2014133093A1 (ja) | 2013-02-28 | 2014-09-04 | 独立行政法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
WO2014175160A1 (ja) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体 |
WO2014183885A1 (en) | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
WO2014185550A1 (en) | 2013-05-16 | 2014-11-20 | Kyoto University | Method for determining prognosis of cancer |
WO2014208482A1 (ja) | 2013-06-24 | 2014-12-31 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤 |
EP2824183A1 (en) | 2005-04-08 | 2015-01-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor VIII |
WO2015020212A1 (ja) | 2013-08-09 | 2015-02-12 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2015041310A1 (ja) | 2013-09-20 | 2015-03-26 | 中外製薬株式会社 | 抗プロテインc抗体による出血性疾患の治療 |
EP2853544A1 (en) | 2007-11-15 | 2015-04-01 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
WO2015056808A1 (en) | 2013-10-15 | 2015-04-23 | Genefrontier Corporation | Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases |
WO2015068781A1 (ja) | 2013-11-06 | 2015-05-14 | 国立大学法人大阪大学 | インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体 |
WO2015068847A1 (ja) | 2013-11-11 | 2015-05-14 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
WO2015067986A1 (en) | 2013-11-07 | 2015-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neuregulin allosteric anti-her3 antibody |
WO2015083764A1 (ja) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ |
WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
WO2015099165A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | 等電点の低い抗体の精製方法 |
WO2015097928A1 (ja) | 2013-12-24 | 2015-07-02 | 中外製薬株式会社 | 可溶性gpc3タンパク質の測定方法 |
WO2015150900A2 (en) | 2014-03-31 | 2015-10-08 | Debiopharm International Sa | Fgfr fusions |
WO2015158851A1 (en) | 2014-04-16 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
EP3050963A1 (en) | 2005-03-31 | 2016-08-03 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2016128349A1 (en) | 2015-02-09 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection |
WO2016162368A1 (en) | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-invasive imaging of tumor pd-l1 expression |
WO2016166014A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
US9499838B2 (en) | 2001-05-11 | 2016-11-22 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
WO2017005847A1 (en) | 2015-07-07 | 2017-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to myosin 18a and uses thereof |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
WO2017046994A1 (en) | 2015-09-18 | 2017-03-23 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
EP3153526A1 (en) | 2008-01-31 | 2017-04-12 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
WO2017059551A1 (en) | 2015-10-08 | 2017-04-13 | Zymeworks Inc. | Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof |
WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
WO2017079335A1 (en) | 2015-11-03 | 2017-05-11 | Regents Of The University Of Minnesota | Cd200 inhibitors and methods of use thereof |
WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
WO2017144668A1 (en) | 2016-02-26 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for btla and uses thereof |
WO2017159287A1 (ja) | 2016-03-14 | 2017-09-21 | 中外製薬株式会社 | 癌の治療に用いるための細胞傷害誘導治療剤 |
WO2017170334A1 (ja) | 2016-03-28 | 2017-10-05 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9809653B2 (en) | 2012-12-27 | 2017-11-07 | Sanofi | Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof |
WO2018020000A1 (en) | 2016-07-29 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies targeting tumor associated macrophages and uses thereof |
WO2018047813A1 (en) | 2016-09-06 | 2018-03-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
WO2018079740A1 (ja) | 2016-10-28 | 2018-05-03 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
WO2018091720A1 (en) | 2016-11-21 | 2018-05-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of metastases |
WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
EP3348639A2 (en) | 2005-06-10 | 2018-07-18 | Chugai Seiyaku Kabushiki Kaisha | Sc(fv)2 site-directed mutant |
US10059746B2 (en) | 2011-04-04 | 2018-08-28 | University Of Iowa Research Foundation | Methods of improving vaccine immunogenicity |
WO2018158398A1 (en) | 2017-03-02 | 2018-09-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
WO2018174274A1 (ja) | 2017-03-24 | 2018-09-27 | 全薬工業株式会社 | 抗IgM/B細胞表面抗原二重特異性抗体 |
WO2018181870A1 (ja) | 2017-03-31 | 2018-10-04 | 公立大学法人奈良県立医科大学 | 血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物 |
WO2018189381A1 (en) | 2017-04-14 | 2018-10-18 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating lung cancers |
WO2018189379A1 (en) | 2017-04-14 | 2018-10-18 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating cancers |
WO2018199214A1 (ja) | 2017-04-27 | 2018-11-01 | 中外製薬株式会社 | 薬物動態が改善された血液凝固第ix因子 |
US10166304B2 (en) | 2014-07-11 | 2019-01-01 | Regents Of The University Of Minnesota | Antibody fragments for detecting cancer and methods of use |
WO2019020480A1 (en) | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
EP3450459A2 (en) | 2009-12-28 | 2019-03-06 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
WO2019057933A1 (en) | 2017-09-21 | 2019-03-28 | Imcheck Therapeutics Sas | ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF |
WO2019107384A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
WO2019131988A1 (en) | 2017-12-28 | 2019-07-04 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2019140150A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
WO2019189780A1 (ja) | 2018-03-30 | 2019-10-03 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2019225568A1 (ja) | 2018-05-21 | 2019-11-28 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
WO2019230856A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | Nav1.7モノクローナル抗体 |
US10509035B2 (en) | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
WO2020022499A1 (ja) | 2018-07-27 | 2020-01-30 | 国立大学法人大阪大学 | 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物 |
WO2020059847A1 (ja) | 2018-09-21 | 2020-03-26 | 国立大学法人 東京医科歯科大学 | ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物 |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
WO2020094609A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
WO2020120786A1 (en) | 2018-12-14 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
WO2020138489A1 (ja) | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ccr8抗体 |
WO2020153467A1 (ja) | 2019-01-24 | 2020-07-30 | 中外製薬株式会社 | 新規がん抗原及びそれらの抗原に対する抗体 |
WO2020169472A2 (en) | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
WO2020175689A1 (ja) | 2019-02-28 | 2020-09-03 | 学校法人順天堂 | 切断型の変異型Calreticulinに結合する抗体、及び骨髄増殖性腫瘍の診断、予防又は治療薬 |
WO2020188086A1 (en) | 2019-03-20 | 2020-09-24 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
WO2020189748A1 (ja) | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ |
WO2020193520A1 (en) | 2019-03-25 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
WO2020209318A1 (ja) | 2019-04-10 | 2020-10-15 | 中外製薬株式会社 | Fc領域改変抗体の精製方法 |
WO2020212593A1 (en) | 2019-04-18 | 2020-10-22 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
US10822416B2 (en) | 2016-03-23 | 2020-11-03 | Mabspace Biosciences (Suzhou) Co., Ltd | Anti-PD-L1 antibodies |
WO2020246563A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | 抗体切断部位結合分子 |
US10906978B2 (en) | 2015-01-23 | 2021-02-02 | Sanofi | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
WO2021023624A1 (en) | 2019-08-02 | 2021-02-11 | Orega Biotech | Novel il-17b antibodies |
US10941203B2 (en) | 2017-03-15 | 2021-03-09 | Tsinghua University | Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma |
WO2021058729A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof |
WO2021058763A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance antibodies and uses thereof |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
WO2021099600A1 (en) | 2019-11-22 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
WO2021110995A1 (en) | 2019-12-04 | 2021-06-10 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
US11085929B2 (en) | 2017-08-31 | 2021-08-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry |
WO2021174034A1 (en) | 2020-02-28 | 2021-09-02 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
WO2021182572A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182574A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021193928A1 (ja) | 2020-03-27 | 2021-09-30 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
WO2021200131A1 (ja) | 2020-03-30 | 2021-10-07 | 国立研究開発法人国立がん研究センター | 抗体薬物複合体 |
WO2021206078A1 (ja) | 2020-04-06 | 2021-10-14 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
WO2021210667A1 (ja) | 2020-04-17 | 2021-10-21 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
WO2021214223A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox |
WO2021214222A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil |
WO2021214227A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab |
WO2021214221A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri |
WO2021228956A1 (en) | 2020-05-12 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas |
WO2021235537A1 (ja) | 2020-05-22 | 2021-11-25 | 中外製薬株式会社 | 凝固第viii因子(f.viii)機能代替活性を有する物質を中和する抗体 |
WO2021261546A1 (ja) | 2020-06-24 | 2021-12-30 | 国立大学法人 東京大学 | 光増感色素 |
WO2022004760A1 (ja) | 2020-06-30 | 2022-01-06 | 塩野義製薬株式会社 | 抗ccr8抗体と化学療法剤の併用 |
WO2022025220A1 (ja) | 2020-07-31 | 2022-02-03 | 中外製薬株式会社 | キメラ受容体を発現する細胞を含む医薬組成物 |
WO2022025030A1 (ja) | 2020-07-28 | 2022-02-03 | 中外製薬株式会社 | 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤 |
WO2022048883A1 (en) | 2020-09-04 | 2022-03-10 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2022124247A1 (ja) | 2020-12-09 | 2022-06-16 | 国立大学法人 東京医科歯科大学 | 前頭側頭葉変性症の予防又は治療剤 |
WO2022129609A2 (en) | 2020-12-18 | 2022-06-23 | Ac Immune Sa | Antibody delivery |
US11377503B2 (en) | 2018-06-18 | 2022-07-05 | Innate Pharma | Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide |
WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
EP4056993A1 (en) | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
WO2022270523A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2022270524A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023008459A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023006919A1 (en) | 2021-07-29 | 2023-02-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF |
WO2023008461A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023012343A1 (en) | 2021-08-06 | 2023-02-09 | Institut Du Cancer De Montpellier | Methods for the treatment of cancer |
US11578136B2 (en) | 2017-03-16 | 2023-02-14 | Innate Pharma | Compositions and methods for treating cancer |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2023048231A1 (ja) | 2021-09-24 | 2023-03-30 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
WO2023058723A1 (ja) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | プレフィルドシリンジ製剤の調製方法 |
WO2023057871A1 (en) | 2021-10-04 | 2023-04-13 | Novartis Ag | Surfactant stabilizers |
WO2023074888A1 (ja) | 2021-11-01 | 2023-05-04 | 塩野義製薬株式会社 | 新規なNav1.7モノクローナル抗体 |
WO2023079057A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
WO2023088359A1 (zh) | 2021-11-18 | 2023-05-25 | 合源生物科技(天津)有限公司 | 靶向bcma的嵌合抗原受体及其应用 |
WO2023100975A1 (ja) | 2021-12-01 | 2023-06-08 | 中外製薬株式会社 | 抗体含有製剤の調製方法 |
US11680105B2 (en) | 2019-01-17 | 2023-06-20 | Regents Of The University Of Minnesota | Antibody fragments for detecting cancer and methods of use |
EP4218816A2 (en) | 2014-06-20 | 2023-08-02 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
WO2023170240A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
WO2024180192A1 (en) | 2023-03-01 | 2024-09-06 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5 |
EP4427763A1 (en) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037779A1 (en) * | 1998-01-22 | 1999-07-29 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
CA2341029A1 (en) * | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
WO2000010608A1 (fr) * | 1998-08-24 | 2000-03-02 | Meiji Milk Products Co., Ltd. | Medicament pour le traitement et/ou la prevention de l'arteriosclerose et de la reangiostenose post-actp |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
US20050222060A1 (en) * | 2002-03-15 | 2005-10-06 | Bot Adrian L | Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs |
US20070037769A1 (en) * | 2003-03-14 | 2007-02-15 | Multicell Immunotherapeutics, Inc. | Compositions and methods to treat and control tumors by loading antigen presenting cells |
JP4753578B2 (ja) * | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
CN1795274A (zh) * | 2003-03-26 | 2006-06-28 | 多单元免疫治疗公司 | 诱导细胞死亡和/或凋亡的选定的rna基序 |
JP2007501011A (ja) * | 2003-08-01 | 2007-01-25 | ジェネンテック・インコーポレーテッド | 制限多様性配列を有する結合型ポリペプチド |
WO2005074417A2 (en) * | 2003-09-03 | 2005-08-18 | Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
FI122368B (fi) * | 2003-11-06 | 2011-12-30 | Valtion Teknillinen | Menetelmä huokoisen muovikalvon valmistamiseksi ja muovikalvo |
CN101133083A (zh) | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | 人源化的抗cd47抗体 |
EP1831258B2 (en) * | 2004-12-28 | 2023-06-07 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
US20090291437A1 (en) * | 2005-11-02 | 2009-11-26 | O'brien Sean | Methods for targeting quadruplex sequences |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) * | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
EP2038306B1 (en) | 2006-06-30 | 2014-12-03 | Novo Nordisk A/S | Anti-nkg2a antibodies and uses thereof |
US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
JP5774312B2 (ja) | 2008-01-24 | 2015-09-09 | ノボ・ノルデイスク・エー/エス | ヒト化抗ヒトnkg2aモノクローナル抗体 |
WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
EP2566973A4 (en) | 2010-05-04 | 2013-11-27 | Medimmune Llc | OPTIMIZED DIAGNOSIS AND TREATMENT OF MUSCLE DISTORTIONS |
WO2012142174A1 (en) | 2011-04-12 | 2012-10-18 | Electronic Biosciences Inc. | Site specific chemically modified nanopore devices |
BR112013032217B1 (pt) | 2011-06-17 | 2021-01-19 | Novo Nordisk A/S | uso de um anticorpo anti-nkg2a |
EP2861998B1 (en) | 2012-06-18 | 2020-07-22 | Electronic Biosciences Inc. | Cell-free assay device and methods of use |
US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
EP3704151A4 (en) * | 2017-11-01 | 2021-07-28 | NantBio, Inc. | EMT PATH BLOCKING IINTERLEUKIN 8 AND CONTROLLING CARCINOUS STEM CELLS |
US12060427B2 (en) | 2018-03-28 | 2024-08-13 | Mitsubishi Tanabe Pharma Corporat | Drug conjugates of cMET monoclonal binding agents, and uses thereof |
EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62201598A (ja) * | 1986-02-28 | 1987-09-05 | Teijin Ltd | マウス−ヒトキメラ抗体h鎖、それをコ−ドするキメラdna配列、プラスミドおよび細胞 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
IE913192A1 (en) * | 1990-09-12 | 1992-02-25 | Scripps Research Inst | Active site of interleukin-8: polypeptide analogs and¹antibodies |
JPH04141095A (ja) * | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗hiv改変抗体および改変抗体の調製方法 |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
US5874080A (en) * | 1994-03-03 | 1999-02-23 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of asthma |
JP3780315B2 (ja) * | 1994-03-03 | 2006-05-31 | ジェネンテク・インコーポレイテッド | 炎症性疾患の処置のための抗il−8モノクローナル抗体 |
-
1995
- 1995-07-12 AT AT95925116T patent/ATE340590T1/de not_active IP Right Cessation
- 1995-07-12 KR KR1019970700191A patent/KR100261941B1/ko not_active IP Right Cessation
- 1995-07-12 CA CA002194907A patent/CA2194907A1/en not_active Abandoned
- 1995-07-12 WO PCT/JP1995/001396 patent/WO1996002576A1/ja active IP Right Grant
- 1995-07-12 HU HU9700093A patent/HU221385B1/hu not_active IP Right Cessation
- 1995-07-12 US US08/765,783 patent/US5994524A/en not_active Expired - Lifetime
- 1995-07-12 DE DE69535243T patent/DE69535243T2/de not_active Expired - Lifetime
- 1995-07-12 AU AU29363/95A patent/AU701342B2/en not_active Ceased
- 1995-07-12 EP EP95925116A patent/EP0770628B9/en not_active Expired - Lifetime
- 1995-10-11 ZA ZA955832A patent/ZA955832B/xx unknown
-
1999
- 1999-10-12 US US09/416,557 patent/US6245894B1/en not_active Expired - Lifetime
-
2000
- 2000-12-07 US US09/730,857 patent/US20020082396A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
J. IMMUNOL. METHODS, 1992, Vol. 149, KO, YUE-CHAU et al., "A Sensitive Enzyme-Linked Immunosorbent Assay for Human Interleukin-8", pages 227-235. * |
J. IMMUNOL., 1989, Vol. 142, No. 3, SANZ I. et al., "VH Sequence of a Human Anti-Sm Autoantibody", pages 883-887. * |
NATURE, 1988, Vol. 332, RIECHMANN L. et al., "Reshaping Human Antibodies for Therapy", pages 323-327. * |
OSAMU KANEMITSU, "Antibody Engineering" 1st Edit., (TOKYO), CHIJIN SHOKAN K.K, 25-01-1995, pages 195-234. * |
THE EMBO JOURNAL, 1988, Vol. 7, No. 7, BULUWELA L. et al., "The Use of Chromosomal Translocations to Study Human Immunoglobulin Gene Organization: Mapping DH Segments Within 35kb of the Cmu Gene and Identification of a New DH Locus", pages 2003-2010. * |
Cited By (487)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US7501552B2 (en) | 1991-08-28 | 2009-03-10 | Medarex, Inc. | Transgenic non-human animals for producing chimeric antibodies |
US5702946A (en) * | 1994-03-03 | 1997-12-30 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders |
US8158419B2 (en) | 1994-03-09 | 2012-04-17 | Medarex, Inc. | Transgenic non-human animals for producing chimeric antibodies |
US8293480B2 (en) | 1994-03-09 | 2012-10-23 | Genpharm International | Transgenic non-human animals for producing chimeric antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1997039772A1 (fr) * | 1996-04-19 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif |
EP1854481A2 (en) | 1996-04-23 | 2007-11-14 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient |
WO1997040215A1 (fr) * | 1996-04-23 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Medicament contre l'infarctus du myocarde contenant comme principe actif un anticorps anti-il-8 |
WO1997049426A1 (fr) * | 1996-06-26 | 1997-12-31 | Chugai Seiyaku Kabushiki Kaisha | Medicaments destines aux lesions pulmonaires aigues dues a des causes indirectes, contenant un anticorps anti-il-8 comme principe actif |
AU709108B2 (en) * | 1996-06-26 | 1999-08-19 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as active ingredient |
WO1998017312A1 (fr) * | 1996-10-22 | 1998-04-30 | Chugai Seiyaku Kabushiki Kaisha | Remede contre les troubles septiques et comprenant un anticorps anti-il-8 en qualite d'ingredient actif |
WO1998024884A1 (en) * | 1996-12-02 | 1998-06-11 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies |
AU747370B2 (en) * | 1996-12-02 | 2002-05-16 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibo dies |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6025158A (en) * | 1997-02-21 | 2000-02-15 | Genentech, Inc. | Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies |
US6870033B1 (en) | 1997-02-21 | 2005-03-22 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
EP2011514A1 (en) | 1997-03-21 | 2009-01-07 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
EP2322216A1 (en) | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
WO1999018997A1 (fr) | 1997-10-14 | 1999-04-22 | Chugai Seiyaku Kabushiki Kaisha | Potentialisateur pour anticorps anti-tumeur lymphoide |
US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US7842789B2 (en) | 1999-01-21 | 2010-11-30 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7214776B2 (en) | 1999-01-21 | 2007-05-08 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US8147830B2 (en) | 1999-01-21 | 2012-04-03 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US7507405B2 (en) | 1999-01-21 | 2009-03-24 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US8652468B2 (en) | 1999-01-21 | 2014-02-18 | Genentech, Inc. | Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates |
US8287863B2 (en) | 1999-08-23 | 2012-10-16 | Chugai Seiyaku Kabushiki Kaisha | Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen |
EP2351483A1 (en) | 1999-10-01 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Prevention and treatment of blood coagulation-related diseases |
EP1987842A1 (en) | 2000-04-28 | 2008-11-05 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitor |
EP1849479A1 (en) | 2000-08-16 | 2007-10-31 | Chugai Seiyaku Kabushiki Kaisha | Ameliorating agent for symptoms resulting from joint diseases |
US10076103B2 (en) | 2000-11-30 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Transgenic transchromosomal rodents for making human antibodies |
US8835712B2 (en) | 2000-11-30 | 2014-09-16 | Medarex, L.L.C. | Transgenic trasnchromosomal rodents for making human antibodies |
US7576258B2 (en) | 2000-11-30 | 2009-08-18 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7816578B2 (en) | 2000-11-30 | 2010-10-19 | Kyowa Hakko Kirin Co., Ltd. | Transgenic transchromosomal rodents for making human antibodies |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US9426970B2 (en) | 2000-11-30 | 2016-08-30 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
WO2002052008A1 (fr) | 2000-12-22 | 2002-07-04 | Kazusa Dna Research Institute Foundation | Nouveaux genes associes au cancer |
US8834876B2 (en) | 2001-02-07 | 2014-09-16 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for hematopoietic tumors |
US7931897B2 (en) | 2001-02-07 | 2011-04-26 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for hematopoietic tumors |
US9499838B2 (en) | 2001-05-11 | 2016-11-22 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
US10448622B2 (en) | 2001-05-11 | 2019-10-22 | E. R. Squibb & Sons, L.L.C. | Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
EP3578168A1 (en) | 2002-02-14 | 2019-12-11 | Chugai Seiyaku Kabushiki Kaisha | Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
WO2003068259A1 (en) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
EP2311489A2 (en) | 2002-02-14 | 2011-04-20 | Chugai Seiyaku Kabushiki Kaisha | Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
US8921527B2 (en) | 2002-02-14 | 2014-12-30 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution formulations |
WO2004019966A1 (ja) | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
EP2075257A1 (en) | 2002-09-04 | 2009-07-01 | Chugai Seiyaku Kabushiki Kaisha | Preparation of antibody using mrl/lpr mouse |
EP3225625A1 (en) | 2002-09-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
EP2261230A1 (en) | 2002-09-11 | 2010-12-15 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
US7622559B2 (en) | 2002-12-16 | 2009-11-24 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (IL-8) |
US8603469B2 (en) | 2002-12-16 | 2013-12-10 | Genmab A/S | Methods of treating cancer with human monoclonal antibodies against interleukin 8 |
US10066012B2 (en) | 2002-12-16 | 2018-09-04 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
US10253093B2 (en) | 2002-12-16 | 2019-04-09 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
US11339215B2 (en) | 2002-12-16 | 2022-05-24 | Cormorant Pharmaceuticals Ab | Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8) |
US8105588B2 (en) | 2002-12-16 | 2012-01-31 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (IL-8) |
US7282568B2 (en) | 2002-12-16 | 2007-10-16 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
EP2228445A1 (en) | 2003-06-18 | 2010-09-15 | Chugai Seiyaku Kabushiki Kaisha | Fucose Transporter |
WO2005007800A3 (ja) * | 2003-07-18 | 2005-03-31 | Mochida Pharm Co Ltd | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
EP2311468A1 (en) | 2003-08-08 | 2011-04-20 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
WO2005014818A1 (ja) | 2003-08-08 | 2005-02-17 | Perseus Proteomics Inc. | 癌高発現遺伝子 |
EP2289944A2 (en) | 2003-10-10 | 2011-03-02 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody substituting for functional proteins |
EP3085783A1 (en) | 2003-10-10 | 2016-10-26 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody substituting for functional proteins |
WO2005035754A1 (ja) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
EP2311945A1 (en) | 2003-10-14 | 2011-04-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies substituting for functional proteins |
EP2314317A2 (en) | 2004-07-09 | 2011-04-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
EP2898897A2 (en) | 2004-07-09 | 2015-07-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
EP2216046A2 (en) | 2004-07-09 | 2010-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
EP2208783A1 (en) | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
EP2216404A1 (en) | 2004-12-22 | 2010-08-11 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
EP3050963A1 (en) | 2005-03-31 | 2016-08-03 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
EP2824183A1 (en) | 2005-04-08 | 2015-01-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor VIII |
WO2006132363A1 (ja) | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
EP3348639A2 (en) | 2005-06-10 | 2018-07-18 | Chugai Seiyaku Kabushiki Kaisha | Sc(fv)2 site-directed mutant |
WO2007046439A1 (ja) | 2005-10-18 | 2007-04-26 | National Institute Of Agrobiological Sciences | 抗体を産生するトランスジェニックカイコとその製造方法 |
WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
EP3056568A1 (en) | 2006-03-31 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
EP4342995A2 (en) | 2006-03-31 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
WO2007114325A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
EP4218801A2 (en) | 2006-03-31 | 2023-08-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
US8232449B2 (en) | 2006-03-31 | 2012-07-31 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9220244B2 (en) | 2006-03-31 | 2015-12-29 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
WO2007129457A1 (ja) | 2006-04-25 | 2007-11-15 | The University Of Tokyo | アルツハイマー病および癌の治療薬 |
WO2007142325A1 (ja) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | 炎症性疾患の予防または治療剤 |
EP2371393A1 (en) | 2006-06-08 | 2011-10-05 | Chugai Seiyaku Kabushiki Kaisha | Preventive or remedy for inflammatory disease |
WO2007145227A1 (ja) | 2006-06-14 | 2007-12-21 | Chugai Seiyaku Kabushiki Kaisha | 造血幹細胞増加促進剤 |
WO2007148417A1 (en) | 2006-06-21 | 2007-12-27 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to fzd10 and uses thereof |
EP2386577A2 (en) | 2006-06-21 | 2011-11-16 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof |
WO2008007755A1 (fr) | 2006-07-13 | 2008-01-17 | Chugai Seiyaku Kabushiki Kaisha | inducteur de mort cellulaire |
EP2574625A1 (en) | 2006-07-21 | 2013-04-03 | Chugai Seiyaku Kabushiki Kaisha | Remedy for renal disease |
WO2008010556A1 (fr) | 2006-07-21 | 2008-01-24 | Chugai Seiyaku Kabushiki Kaisha | Médicament agissant contre une maladie rénale |
WO2008012049A1 (en) | 2006-07-24 | 2008-01-31 | Institut Pasteur | Post-translationally modified neurotrophins |
EP2548576A1 (en) | 2006-08-14 | 2013-01-23 | Forerunner Pharma Research Co., Ltd. | Diagnosis of cancer using anti-desmoglein-3 antibodies |
WO2008020586A1 (en) | 2006-08-14 | 2008-02-21 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
EP3111955A1 (en) | 2006-08-14 | 2017-01-04 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
WO2008047723A1 (en) | 2006-10-12 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-ereg antibody |
WO2008047925A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif |
WO2008047914A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif |
EP3040347A2 (en) | 2006-10-20 | 2016-07-06 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
WO2008072723A1 (ja) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断 |
WO2008081942A1 (ja) | 2007-01-05 | 2008-07-10 | The University Of Tokyo | 抗prg-3抗体を用いる癌の診断および治療 |
WO2008093688A1 (ja) | 2007-01-30 | 2008-08-07 | Forerunner Pharma Research Co., Ltd. | キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法 |
WO2008105560A1 (ja) | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | 抗grp78抗体を有効成分として含む医薬組成物 |
WO2008111597A1 (ja) | 2007-03-12 | 2008-09-18 | Chugai Seiyaku Kabushiki Kaisha | Hlaクラスiを認識する抗体を有効成分として含有する化学療法剤耐性癌治療剤、およびその利用 |
US7875705B2 (en) | 2007-05-28 | 2011-01-25 | The University Of Tokyo | Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody |
WO2009001840A1 (ja) | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | ADCC活性又はCDC活性を有する抗Prominin-1抗体 |
WO2009008414A1 (ja) | 2007-07-10 | 2009-01-15 | Shionogi & Co., Ltd. | Mmp13に対する中和活性を有するモノクローナル抗体 |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP4368721A2 (en) | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
EP4339294A2 (en) | 2007-09-26 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US8497355B2 (en) | 2007-09-28 | 2013-07-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
EP2617736A1 (en) | 2007-09-28 | 2013-07-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having improved kinetics in plasma |
EP2584043A2 (en) | 2007-09-28 | 2013-04-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having improved kinetics in plasma |
WO2009041062A1 (ja) | 2007-09-28 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 血漿中動態が改善されたグリピカン3抗体 |
WO2009051108A1 (ja) | 2007-10-15 | 2009-04-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
WO2009063970A1 (ja) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | 抗gpr49抗体を用いる癌の診断および治療 |
EP2853544A1 (en) | 2007-11-15 | 2015-04-01 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
WO2009072604A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 抗nr10抗体、およびその利用 |
WO2009072598A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 掻痒症治療剤 |
EP3095862A1 (en) | 2007-12-05 | 2016-11-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody and use thereof |
WO2009084659A1 (ja) | 2007-12-27 | 2009-07-09 | Chugai Seiyaku Kabushiki Kaisha | 高濃度抗体含有溶液製剤 |
EP3064512A2 (en) | 2008-01-11 | 2016-09-07 | The University of Tokyo | Anti-cldn6 antibody |
EP4282428A2 (en) | 2008-01-11 | 2023-11-29 | The University of Tokyo | Anti-cldn6 antibody |
WO2009087978A1 (ja) | 2008-01-11 | 2009-07-16 | The University Of Tokyo | 抗cldn6抗体 |
US11685792B2 (en) | 2008-01-31 | 2023-06-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity |
EP3153526A1 (en) | 2008-01-31 | 2017-04-12 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
US10662253B2 (en) | 2008-01-31 | 2020-05-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity |
WO2009122667A1 (ja) | 2008-04-04 | 2009-10-08 | 中外製薬株式会社 | 肝癌治療剤 |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2708558A2 (en) | 2008-04-11 | 2014-03-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2009125825A1 (ja) | 2008-04-11 | 2009-10-15 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP3514180A1 (en) | 2008-04-11 | 2019-07-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP4238993A2 (en) | 2008-04-11 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP3056513A1 (en) | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
EP2708559A2 (en) | 2008-04-11 | 2014-03-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2116261A1 (en) | 2008-05-07 | 2009-11-11 | Institut Pasteur | Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof |
WO2009136373A1 (en) | 2008-05-07 | 2009-11-12 | Institut Pasteur | Sub-region of a plasmodium protein with improved vaccine potential, and medical uses thereof |
WO2009147781A1 (ja) | 2008-06-02 | 2009-12-10 | 国立大学法人東京大学 | 抗がん剤 |
WO2010005068A1 (ja) | 2008-07-10 | 2010-01-14 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
WO2010016526A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
WO2010038610A1 (ja) | 2008-09-30 | 2010-04-08 | オリエンタル酵母工業株式会社 | 新しい軟骨細胞増殖及び分化誘導剤 |
WO2010040766A1 (en) | 2008-10-07 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
WO2010055950A1 (ja) | 2008-11-17 | 2010-05-20 | 財団法人ヒューマンサイエンス振興財団 | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
EP2949672A1 (en) | 2008-12-05 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody, and use thereof |
WO2010064697A1 (ja) | 2008-12-05 | 2010-06-10 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
WO2010074049A1 (ja) | 2008-12-22 | 2010-07-01 | 株式会社 未来創薬研究所 | 抗hs6st2抗体及びその用途 |
WO2010073694A1 (ja) | 2008-12-25 | 2010-07-01 | 国立大学法人東京大学 | 抗tm4sf20抗体を用いた癌の診断と治療 |
WO2010074192A1 (ja) | 2008-12-26 | 2010-07-01 | 国立大学法人東京大学 | 抗lgr7抗体を用いる癌の診断および治療 |
EP3002296A1 (en) | 2009-03-17 | 2016-04-06 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
WO2010106051A1 (en) | 2009-03-17 | 2010-09-23 | Universite De La Mediterranee | Btla antibodies and uses thereof |
WO2010113117A2 (en) | 2009-03-30 | 2010-10-07 | Edimer Biotech S.A. | Preparation of isolated agonist anti-edar monoclonal antibodies |
EP2899212A1 (en) | 2009-03-30 | 2015-07-29 | Edimer Biotech S.a. | Preparation of isolated agonist anti-EDAR monoclonal antibodies |
WO2010119691A1 (ja) | 2009-04-16 | 2010-10-21 | 国立大学法人東京大学 | 抗tmprss11e抗体を用いた癌の診断と治療 |
US9017683B2 (en) | 2009-05-01 | 2015-04-28 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
WO2010126137A1 (ja) | 2009-05-01 | 2010-11-04 | 国立大学法人 東京大学 | 抗カドヘリン抗体 |
US8455249B2 (en) | 2009-05-01 | 2013-06-04 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
WO2010137654A1 (ja) | 2009-05-29 | 2010-12-02 | 株式会社未来創薬研究所 | Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
WO2011021381A1 (ja) | 2009-08-17 | 2011-02-24 | 株式会社未来創薬研究所 | 抗hb-egf抗体を有効成分として含む医薬組成物 |
WO2011037160A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | Hlaクラスiを認識する抗体 |
WO2011057188A1 (en) | 2009-11-06 | 2011-05-12 | Idexx Laboratories, Inc. | Canine anti-cd20 antibodies |
EP3450459A2 (en) | 2009-12-28 | 2019-03-06 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
WO2011090088A1 (ja) | 2010-01-20 | 2011-07-28 | 中外製薬株式会社 | 安定化抗体含有溶液製剤 |
EP3892292A2 (en) | 2010-01-20 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing liquid formulations |
EP3378486A2 (en) | 2010-01-20 | 2018-09-26 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing liquid formulations |
WO2011093097A1 (ja) | 2010-01-29 | 2011-08-04 | 株式会社未来創薬研究所 | 抗dll3抗体 |
EP3907242A1 (en) | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
WO2011092989A1 (ja) | 2010-01-29 | 2011-08-04 | 東レ株式会社 | ポリ乳酸系樹脂シート |
EP3342786A1 (en) | 2010-01-29 | 2018-07-04 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
WO2011096517A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096519A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096534A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096528A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096533A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011099524A1 (ja) | 2010-02-10 | 2011-08-18 | 富士フイルムRiファーマ株式会社 | 放射性金属標識抗カドヘリン抗体 |
WO2011105573A1 (ja) | 2010-02-26 | 2011-09-01 | 株式会社未来創薬研究所 | 抗icam3抗体およびその用途 |
WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP3181581A1 (en) | 2010-03-30 | 2017-06-21 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
EP3702368A1 (en) | 2010-03-30 | 2020-09-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules that promote antigen clearance |
WO2011122011A2 (en) | 2010-03-30 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
WO2012005076A1 (ja) | 2010-07-08 | 2012-01-12 | 本田技研工業株式会社 | 高周波加熱用コイル |
WO2012010696A1 (en) | 2010-07-23 | 2012-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
WO2012043747A1 (ja) | 2010-09-30 | 2012-04-05 | 独立行政法人理化学研究所 | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 |
WO2012061120A1 (en) | 2010-10-25 | 2012-05-10 | Regents Of The University Of Minnesota | Therapeutic composition for treatment of glioblastoma |
US9662377B2 (en) | 2010-10-25 | 2017-05-30 | Regents Of The University Of Minneosta | Therapeutic composition for treatment of glioblastoma |
US9364505B2 (en) | 2010-10-25 | 2016-06-14 | Regents Of The University Of Minnesota | Therapeutic composition for treatment of glioblastoma |
WO2012057328A1 (ja) | 2010-10-29 | 2012-05-03 | 株式会社ペルセウスプロテオミクス | 高い内在化能力を有する抗cdh3抗体 |
EP3708586A1 (en) | 2010-10-29 | 2020-09-16 | Perseus Proteomics Inc. | Anti-cdh3 antibody having high internalization capacity |
EP3404043A1 (en) | 2010-10-29 | 2018-11-21 | Perseus Proteomics Inc. | Anti-cdh3 antibody having high internalization capacity |
EP3318633A1 (en) | 2010-11-17 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
WO2012067176A1 (ja) | 2010-11-17 | 2012-05-24 | 中外製薬株式会社 | 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子 |
WO2012073985A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
EP4279513A2 (en) | 2010-11-30 | 2023-11-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4279512A2 (en) | 2010-11-30 | 2023-11-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4303237A2 (en) | 2010-11-30 | 2024-01-10 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP3434767A1 (en) | 2010-11-30 | 2019-01-30 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4231014A2 (en) | 2010-11-30 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP4303236A2 (en) | 2010-11-30 | 2024-01-10 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4279511A2 (en) | 2010-11-30 | 2023-11-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2012080351A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
WO2012085132A1 (en) | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
WO2012090939A1 (ja) | 2010-12-27 | 2012-07-05 | 国立大学法人名古屋大学 | 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法 |
WO2012093704A1 (ja) | 2011-01-07 | 2012-07-12 | 中外製薬株式会社 | 抗体の物性を改善させる方法 |
EP3539991A1 (en) | 2011-01-07 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
WO2012107531A1 (en) | 2011-02-09 | 2012-08-16 | Ruprecht-Karls-Univeristät Heidelberg | B-type plexin antagonists and uses thereof |
US9198966B2 (en) | 2011-02-09 | 2015-12-01 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
WO2012115241A1 (ja) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | FcγRIIb特異的Fc抗体 |
WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
EP3825325A2 (en) | 2011-03-30 | 2021-05-26 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
EP3590969A1 (en) | 2011-03-31 | 2020-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
WO2012131004A2 (en) | 2011-03-31 | 2012-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
WO2012133914A1 (ja) | 2011-03-31 | 2012-10-04 | オリエンタル酵母工業株式会社 | Ranklアンタゴニストを含む癌免疫増強剤 |
US10059746B2 (en) | 2011-04-04 | 2018-08-28 | University Of Iowa Research Foundation | Methods of improving vaccine immunogenicity |
WO2012144208A1 (ja) | 2011-04-18 | 2012-10-26 | 国立大学法人東京大学 | 抗itm2a抗体を用いる癌の診断および治療 |
WO2012156532A1 (en) | 2011-05-19 | 2012-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human-her3 antibodies and uses thereof |
WO2012175691A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
WO2012175692A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
EP4011913A1 (en) | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
WO2013008098A1 (en) | 2011-07-08 | 2013-01-17 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Antibodies for the treatment and prevention of thrombosis |
WO2013008100A1 (en) | 2011-07-08 | 2013-01-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment and prevention of thrombosis |
EP2543679A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
WO2013008099A1 (en) | 2011-07-08 | 2013-01-17 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543678A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543677A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
WO2013017656A1 (en) | 2011-08-02 | 2013-02-07 | Medizinische Universität Wien | Antagonists of ribonucleases for treating obesity |
WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018889A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018883A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013017691A1 (en) | 2011-08-04 | 2013-02-07 | Medizinische Universität Innsbruck | Cahgt1p inhibitors for use in the treatment of candidiasis |
WO2013024517A1 (ja) | 2011-08-12 | 2013-02-21 | 国立感染症研究所 | アスペルギルス フミガーツス感染症の検査、予防及び治療のための方法並びに組成物 |
WO2013027802A1 (ja) | 2011-08-23 | 2013-02-28 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ddr1抗体 |
WO2013035824A1 (ja) | 2011-09-07 | 2013-03-14 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞の分離 |
EP3549956A2 (en) | 2011-09-30 | 2019-10-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a fcrn-binding domain that promotes antigen clearance |
WO2013046704A2 (en) | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE |
WO2013046722A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | イオン濃度依存性結合分子ライブラリ |
WO2013047729A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 標的抗原に対する免疫応答を誘導する抗原結合分子 |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
EP4324850A2 (en) | 2011-09-30 | 2024-02-21 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a fcrn-binding domain that promotes antigen clearance |
WO2013047752A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 抗原の消失を促進する抗原結合分子 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
EP3680251A1 (en) | 2011-09-30 | 2020-07-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules for promoting elimination of antigens |
WO2013051294A1 (ja) | 2011-10-05 | 2013-04-11 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
EP3617313A1 (en) | 2011-10-05 | 2020-03-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain |
WO2013062083A1 (ja) | 2011-10-28 | 2013-05-02 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞特異的分子 |
EP3603671A2 (en) | 2011-10-28 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
WO2013065708A1 (ja) | 2011-10-31 | 2013-05-10 | 中外製薬株式会社 | 重鎖と軽鎖の会合が制御された抗原結合分子 |
EP3517550A1 (en) | 2011-11-30 | 2019-07-31 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
WO2013081143A1 (ja) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬 |
WO2013100120A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤 |
WO2013106572A1 (en) | 2012-01-11 | 2013-07-18 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Bispecific antibody fragments for neurological disease proteins and methods of use |
WO2013118858A1 (ja) | 2012-02-09 | 2013-08-15 | 中外製薬株式会社 | 抗体のFc領域改変体 |
WO2013125630A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125636A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125640A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125654A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
EP3738980A1 (en) | 2012-02-24 | 2020-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib |
WO2013147153A1 (ja) | 2012-03-29 | 2013-10-03 | 株式会社未来創薬研究所 | 抗lamp5抗体およびその利用 |
WO2013147169A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び/又は予防用医薬組成物 |
WO2013147176A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
WO2013150623A1 (ja) | 2012-04-04 | 2013-10-10 | 株式会社ペルセウスプロテオミクス | 抗cdh3(p-カドヘリン)抗体の薬剤コンジュゲート |
WO2013161814A1 (ja) | 2012-04-23 | 2013-10-31 | ジーンフロンティア株式会社 | 抗ヒトcd69抗体、及びその医薬用途 |
WO2013168820A1 (ja) | 2012-05-11 | 2013-11-14 | 公益財団法人微生物化学研究会 | 抗cxadr抗体 |
WO2013180201A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 会合化した抗原を消失させる抗原結合分子 |
EP3892638A1 (en) | 2012-05-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
EP4310191A2 (en) | 2012-06-14 | 2024-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified fc region |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
WO2014001368A1 (en) | 2012-06-25 | 2014-01-03 | Orega Biotech | Il-17 antagonist antibodies |
WO2014021339A1 (ja) | 2012-07-30 | 2014-02-06 | 国立大学法人名古屋大学 | ヒトミッドカインに対するモノクローナル抗体 |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
WO2014030728A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | FcγRIIb特異的Fc領域改変体 |
EP3597747A1 (en) | 2012-08-24 | 2020-01-22 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
WO2014033327A1 (en) | 2012-09-03 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos for treating graft-versus-host disease |
WO2014042251A1 (ja) | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
WO2014051022A1 (ja) | 2012-09-27 | 2014-04-03 | 中外製薬株式会社 | Fgfr3融合遺伝子およびそれを標的とする医薬 |
WO2014050926A1 (ja) | 2012-09-28 | 2014-04-03 | 中外製薬株式会社 | 血液凝固反応の評価方法 |
WO2014073292A1 (ja) | 2012-11-09 | 2014-05-15 | ジーンフロンティア株式会社 | 癌治療のための抗adam28抗体 |
EP3473718A1 (en) | 2012-11-09 | 2019-04-24 | GeneFrontier Corporation | Anti-adam28 antibody for treating cancer |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
EP3594243A1 (en) | 2012-11-20 | 2020-01-15 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
US9617345B2 (en) | 2012-11-20 | 2017-04-11 | Sanofi | Anti-CEACAM5 antibodies and uses thereof |
US10457739B2 (en) | 2012-11-20 | 2019-10-29 | Sanofi | Anti-CEACAM5 antibodies and uses thereof |
WO2014079886A1 (en) | 2012-11-20 | 2014-05-30 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
US11332542B2 (en) | 2012-11-20 | 2022-05-17 | Sanofi | Anti-CEACAM5 antibodies and uses thereof |
WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
US9809653B2 (en) | 2012-12-27 | 2017-11-07 | Sanofi | Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof |
WO2014123227A1 (ja) | 2013-02-08 | 2014-08-14 | 株式会社医学生物学研究所 | ヒトnrg1タンパク質に対する抗体 |
WO2014126198A1 (ja) | 2013-02-15 | 2014-08-21 | 株式会社ペルセウスプロテオミクス | 抗cdh3ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用 |
US9644028B2 (en) | 2013-02-15 | 2017-05-09 | Perseus Proteomics Inc. | Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof |
EP3339327A2 (en) | 2013-02-28 | 2018-06-27 | National Cancer Center | Antibody against insoluble fibrin |
WO2014133093A1 (ja) | 2013-02-28 | 2014-09-04 | 独立行政法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
WO2014175160A1 (ja) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体 |
WO2014185550A1 (en) | 2013-05-16 | 2014-11-20 | Kyoto University | Method for determining prognosis of cancer |
WO2014183885A1 (en) | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
WO2014208482A1 (ja) | 2013-06-24 | 2014-12-31 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤 |
WO2015020212A1 (ja) | 2013-08-09 | 2015-02-12 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2015041310A1 (ja) | 2013-09-20 | 2015-03-26 | 中外製薬株式会社 | 抗プロテインc抗体による出血性疾患の治療 |
WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
WO2015056808A1 (en) | 2013-10-15 | 2015-04-23 | Genefrontier Corporation | Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases |
WO2015068781A1 (ja) | 2013-11-06 | 2015-05-14 | 国立大学法人大阪大学 | インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体 |
WO2015067986A1 (en) | 2013-11-07 | 2015-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neuregulin allosteric anti-her3 antibody |
WO2015068847A1 (ja) | 2013-11-11 | 2015-05-14 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
WO2015083764A1 (ja) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ |
EP3763813A1 (en) | 2013-12-04 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
WO2015097928A1 (ja) | 2013-12-24 | 2015-07-02 | 中外製薬株式会社 | 可溶性gpc3タンパク質の測定方法 |
WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
EP3581179A1 (en) | 2013-12-27 | 2019-12-18 | Chugai Seiyaku Kabushiki Kaisha | Fgfr gatekeeper mutant gene and drug targeting same |
WO2015099165A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | 等電点の低い抗体の精製方法 |
EP3572093A1 (en) | 2014-03-31 | 2019-11-27 | Debiopharm International SA | Fgfr fusions |
WO2015150900A2 (en) | 2014-03-31 | 2015-10-08 | Debiopharm International Sa | Fgfr fusions |
WO2015158851A1 (en) | 2014-04-16 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
EP4218816A2 (en) | 2014-06-20 | 2023-08-02 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
US10166304B2 (en) | 2014-07-11 | 2019-01-01 | Regents Of The University Of Minnesota | Antibody fragments for detecting cancer and methods of use |
EP4056993A1 (en) | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US11454633B2 (en) | 2014-12-19 | 2022-09-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US10738111B2 (en) | 2014-12-19 | 2020-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
EP4039710A2 (en) | 2015-01-23 | 2022-08-10 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
US10906978B2 (en) | 2015-01-23 | 2021-02-02 | Sanofi | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
EP3812398A2 (en) | 2015-01-23 | 2021-04-28 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
US10519229B2 (en) | 2015-02-05 | 2019-12-31 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding IL-8 antibodies |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
US11180548B2 (en) | 2015-02-05 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing IL-8 biological activity |
EP3816179A2 (en) | 2015-02-05 | 2021-05-05 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2016128349A1 (en) | 2015-02-09 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection |
WO2016162368A1 (en) | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-invasive imaging of tumor pd-l1 expression |
WO2016166014A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
WO2017005847A1 (en) | 2015-07-07 | 2017-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to myosin 18a and uses thereof |
US10509035B2 (en) | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
JP2017536800A (ja) * | 2015-09-18 | 2017-12-14 | 中外製薬株式会社 | Il−8に結合する抗体およびその使用 |
WO2017046994A1 (en) | 2015-09-18 | 2017-03-23 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
WO2017059551A1 (en) | 2015-10-08 | 2017-04-13 | Zymeworks Inc. | Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof |
WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
EP4410376A2 (en) | 2015-11-03 | 2024-08-07 | Regents of the University of Minnesota | Cd200 inhibitors and methods of use thereof |
WO2017079335A1 (en) | 2015-11-03 | 2017-05-11 | Regents Of The University Of Minnesota | Cd200 inhibitors and methods of use thereof |
WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
WO2017144668A1 (en) | 2016-02-26 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for btla and uses thereof |
WO2017159287A1 (ja) | 2016-03-14 | 2017-09-21 | 中外製薬株式会社 | 癌の治療に用いるための細胞傷害誘導治療剤 |
US11753473B2 (en) | 2016-03-23 | 2023-09-12 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-PD-L1 antibodies |
US10822416B2 (en) | 2016-03-23 | 2020-11-03 | Mabspace Biosciences (Suzhou) Co., Ltd | Anti-PD-L1 antibodies |
WO2017170334A1 (ja) | 2016-03-28 | 2017-10-05 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2018020000A1 (en) | 2016-07-29 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies targeting tumor associated macrophages and uses thereof |
US11780912B2 (en) | 2016-08-05 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of IL-8 related diseases |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
WO2018047813A1 (en) | 2016-09-06 | 2018-03-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
US11780908B2 (en) | 2016-09-16 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use |
US10844113B2 (en) | 2016-09-16 | 2020-11-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
WO2018079740A1 (ja) | 2016-10-28 | 2018-05-03 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2018091720A1 (en) | 2016-11-21 | 2018-05-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of metastases |
WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
WO2018158398A1 (en) | 2017-03-02 | 2018-09-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
US10941203B2 (en) | 2017-03-15 | 2021-03-09 | Tsinghua University | Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma |
US12037400B2 (en) | 2017-03-15 | 2024-07-16 | Tsinghua University | Anti-TrkB agonist antibodies binding to D1 domain of TrkB |
EP4095161A1 (en) | 2017-03-15 | 2022-11-30 | Tsinghua University | Novel anti-trkb antibodies |
US11578136B2 (en) | 2017-03-16 | 2023-02-14 | Innate Pharma | Compositions and methods for treating cancer |
US11492399B2 (en) | 2017-03-24 | 2022-11-08 | Zenyaku Kogyo Co., Ltd. | Anti-IgM/B cell surface antigen bispecific antibody |
WO2018174274A1 (ja) | 2017-03-24 | 2018-09-27 | 全薬工業株式会社 | 抗IgM/B細胞表面抗原二重特異性抗体 |
WO2018181870A1 (ja) | 2017-03-31 | 2018-10-04 | 公立大学法人奈良県立医科大学 | 血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物 |
WO2018189381A1 (en) | 2017-04-14 | 2018-10-18 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating lung cancers |
WO2018189379A1 (en) | 2017-04-14 | 2018-10-18 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating cancers |
WO2018199214A1 (ja) | 2017-04-27 | 2018-11-01 | 中外製薬株式会社 | 薬物動態が改善された血液凝固第ix因子 |
WO2019020480A1 (en) | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
US11085929B2 (en) | 2017-08-31 | 2021-08-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry |
WO2019057933A1 (en) | 2017-09-21 | 2019-03-28 | Imcheck Therapeutics Sas | ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF |
WO2019107384A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
WO2019131988A1 (en) | 2017-12-28 | 2019-07-04 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US11572405B2 (en) | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
WO2019140150A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
WO2019189780A1 (ja) | 2018-03-30 | 2019-10-03 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2019225568A1 (ja) | 2018-05-21 | 2019-11-28 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
WO2019230856A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | Nav1.7モノクローナル抗体 |
US11377503B2 (en) | 2018-06-18 | 2022-07-05 | Innate Pharma | Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide |
WO2020022499A1 (ja) | 2018-07-27 | 2020-01-30 | 国立大学法人大阪大学 | 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物 |
WO2020059847A1 (ja) | 2018-09-21 | 2020-03-26 | 国立大学法人 東京医科歯科大学 | ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物 |
WO2020094609A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
WO2020120786A1 (en) | 2018-12-14 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
WO2020138489A1 (ja) | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ccr8抗体 |
US11680105B2 (en) | 2019-01-17 | 2023-06-20 | Regents Of The University Of Minnesota | Antibody fragments for detecting cancer and methods of use |
WO2020153467A1 (ja) | 2019-01-24 | 2020-07-30 | 中外製薬株式会社 | 新規がん抗原及びそれらの抗原に対する抗体 |
WO2020169472A2 (en) | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
WO2020175689A1 (ja) | 2019-02-28 | 2020-09-03 | 学校法人順天堂 | 切断型の変異型Calreticulinに結合する抗体、及び骨髄増殖性腫瘍の診断、予防又は治療薬 |
WO2020189748A1 (ja) | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ |
WO2020188086A1 (en) | 2019-03-20 | 2020-09-24 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
WO2020193520A1 (en) | 2019-03-25 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
WO2020209318A1 (ja) | 2019-04-10 | 2020-10-15 | 中外製薬株式会社 | Fc領域改変抗体の精製方法 |
WO2020212593A1 (en) | 2019-04-18 | 2020-10-22 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
WO2020246563A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | 抗体切断部位結合分子 |
WO2021023624A1 (en) | 2019-08-02 | 2021-02-11 | Orega Biotech | Novel il-17b antibodies |
WO2021058729A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof |
WO2021058763A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance antibodies and uses thereof |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
WO2021078959A1 (en) | 2019-10-23 | 2021-04-29 | Gamamabs Pharma | Amh-competitive antagonist antibody |
WO2021099600A1 (en) | 2019-11-22 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
WO2021110995A1 (en) | 2019-12-04 | 2021-06-10 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
US11879004B2 (en) | 2020-02-28 | 2024-01-23 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
WO2021174034A1 (en) | 2020-02-28 | 2021-09-02 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
WO2021182572A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182574A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2021193928A1 (ja) | 2020-03-27 | 2021-09-30 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
WO2021200131A1 (ja) | 2020-03-30 | 2021-10-07 | 国立研究開発法人国立がん研究センター | 抗体薬物複合体 |
WO2021206078A1 (ja) | 2020-04-06 | 2021-10-14 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
WO2021210667A1 (ja) | 2020-04-17 | 2021-10-21 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
WO2021214222A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil |
WO2021214223A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox |
WO2021214221A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri |
WO2021214227A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab |
WO2021228956A1 (en) | 2020-05-12 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas |
WO2021235537A1 (ja) | 2020-05-22 | 2021-11-25 | 中外製薬株式会社 | 凝固第viii因子(f.viii)機能代替活性を有する物質を中和する抗体 |
WO2021261546A1 (ja) | 2020-06-24 | 2021-12-30 | 国立大学法人 東京大学 | 光増感色素 |
WO2022004760A1 (ja) | 2020-06-30 | 2022-01-06 | 塩野義製薬株式会社 | 抗ccr8抗体と化学療法剤の併用 |
WO2022025030A1 (ja) | 2020-07-28 | 2022-02-03 | 中外製薬株式会社 | 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤 |
WO2022025220A1 (ja) | 2020-07-31 | 2022-02-03 | 中外製薬株式会社 | キメラ受容体を発現する細胞を含む医薬組成物 |
WO2022048883A1 (en) | 2020-09-04 | 2022-03-10 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
WO2022079045A1 (en) | 2020-10-12 | 2022-04-21 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Anti-lilrb antibodies and uses thereof |
EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
WO2022124247A1 (ja) | 2020-12-09 | 2022-06-16 | 国立大学法人 東京医科歯科大学 | 前頭側頭葉変性症の予防又は治療剤 |
WO2022129609A2 (en) | 2020-12-18 | 2022-06-23 | Ac Immune Sa | Antibody delivery |
WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
WO2022270524A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2022270523A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023008459A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023008461A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023006919A1 (en) | 2021-07-29 | 2023-02-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF |
WO2023012343A1 (en) | 2021-08-06 | 2023-02-09 | Institut Du Cancer De Montpellier | Methods for the treatment of cancer |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2023048231A1 (ja) | 2021-09-24 | 2023-03-30 | 株式会社PhotoQ3 | 腫瘍細胞を死滅させるための医薬 |
WO2023057871A1 (en) | 2021-10-04 | 2023-04-13 | Novartis Ag | Surfactant stabilizers |
WO2023058723A1 (ja) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | プレフィルドシリンジ製剤の調製方法 |
WO2023074888A1 (ja) | 2021-11-01 | 2023-05-04 | 塩野義製薬株式会社 | 新規なNav1.7モノクローナル抗体 |
WO2023079057A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
WO2023088359A1 (zh) | 2021-11-18 | 2023-05-25 | 合源生物科技(天津)有限公司 | 靶向bcma的嵌合抗原受体及其应用 |
WO2023100975A1 (ja) | 2021-12-01 | 2023-06-08 | 中外製薬株式会社 | 抗体含有製剤の調製方法 |
WO2023170240A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
WO2023170239A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Methods and tools for conjugation to antibodies |
WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
WO2024180192A1 (en) | 2023-03-01 | 2024-09-06 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5 |
EP4427763A1 (en) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
WO2024184349A1 (en) | 2023-03-06 | 2024-09-12 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
Also Published As
Publication number | Publication date |
---|---|
CA2194907A1 (en) | 1996-02-01 |
US6245894B1 (en) | 2001-06-12 |
EP0770628B9 (en) | 2007-02-28 |
DE69535243T2 (de) | 2007-05-10 |
KR100261941B1 (ko) | 2000-07-15 |
ATE340590T1 (de) | 2006-10-15 |
EP0770628A4 (en) | 2004-10-27 |
EP0770628A1 (en) | 1997-05-02 |
HUT77420A (hu) | 1998-04-28 |
US20020082396A1 (en) | 2002-06-27 |
US5994524A (en) | 1999-11-30 |
EP0770628B1 (en) | 2006-09-27 |
HU221385B1 (en) | 2002-09-28 |
AU2936395A (en) | 1996-02-16 |
DE69535243D1 (de) | 2006-11-09 |
ZA955832B (en) | 1996-04-10 |
AU701342B2 (en) | 1999-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996002576A1 (fr) | Anticorps humain reconstitue contre l'interleukine-8 humaine | |
JP5981688B2 (ja) | ヒトインスリン受容体を介する医薬品の送達 | |
TWI323265B (en) | Antibodies | |
KR101824512B1 (ko) | 과립구-대식세포 콜로니 자극 인자에 대한 항체 | |
WO1994028159A1 (fr) | Anticorps humain reconstruit contre l'interleukine-6 humaine | |
JP5987822B2 (ja) | 癌胎児性抗原に対する抗体及びその使用 | |
RU2746812C1 (ru) | Способы и композиции для лечения амилоидозов | |
HU218140B (hu) | Humán interleukin-6-receptorral szembeni átalakított humán antitest | |
TW201029662A (en) | Novel antigen binding proteins | |
EP1167388A1 (en) | Single-stranded fv inducing apoptosis | |
CA2484420A1 (en) | Antibodies specific for human cd22 and their therapeutic and diagnostic uses | |
JP3865418B2 (ja) | ヒトインターロイキン−8に対する再構成ヒト抗体 | |
US6214973B1 (en) | Reshaped human antibody to human medulloblastoma cells | |
EP1478667A1 (en) | Anti-human tenascin monoclonal antibody | |
RU2159776C2 (ru) | Реконструированные человеческие антитела к человеческому интерлейкину-8 | |
KR100277769B1 (ko) | 항-파스 재조합 항체 및 이에 대한 디엔에이 | |
CA2283540A1 (en) | Anti-fas antibodies | |
CN113166239B (zh) | 抗il-17a抗体及其应用 | |
WO1999018997A1 (fr) | Potentialisateur pour anticorps anti-tumeur lymphoide | |
WO2021190582A1 (zh) | 一种抗ox40抗体药物组合物及其用途 | |
JPH08169900A (ja) | ヒト髄芽腫細胞に対する再構成ヒト抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194723.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS KE KG KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2194907 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995925116 Country of ref document: EP Ref document number: 1019970700191 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08765783 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995925116 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970700191 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970700191 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995925116 Country of ref document: EP |